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I INTRODUCTION 
In 1811 Brodie published his article on the different modes in which 
death is produced by certain vegetable poisons. He described how 
Woorara, a poison with which the Indians of Guiana armed their arrow 
heads (fig. 1), was applied to a wound on a guinea pig, causing it to 
become motionless whilst the heart continued to beat. Brodie found 
that artificial respiration prolonged the heart function for a short 
while. He concluded that the poison acted in some unspecified way 
on the brain and that cessation of the function of this organ was the 
immediate cause of death (Brodie, 1811). 
HOG-ARROW. 
Fi~. 1 Hog-arrow 
In 1812 he told the Society for the Improvement of Animal Chemistry, 
and via them the Royal Society, that he had kept a cat alive after 
administration of Woorara by artificially ventilating the animal for 
several hours. The cat was given to a friend and lived for some years 
thereafter. This experiment was repeated on an ass, which was 
ventilated for more than one hour by means of a pair of bellows and a 
tube introduced into the trachea. Having survived this, the animal was 
allowed to range on an island and was named Wouralia. "Wouralia shall 
be sheltered from wintry storm and when summer comes, she shall feed 
in the finest pasture. No burden shall be placed upon her and she 
shall end her days in peace". Wouralia died on the 15th of February 
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1839, having survived the operation a 1 most 25 years earlier (Brodie, 
1851; Waterton, 1839). 
Woorara was also known as "ourari ". In the 1 anguage of the Tupi 
Indians this word means "the poison with which one can kill birds". 
Later it became "curare". Alexander von Humboldt was the first to 
describe in detail how the poison was prepared from the barks of the 
creeper Chondodendron tomentosum and Strychnos toxi fera. The poi son 
was stored and transported in bamboo tubes, hence the name 
tubocurarine. 
In the mid-1850's Virchow and Thibeaud, and Vulpian performed a 
number of animal experiments for the purpose of investigating whether 
curare and strychnine neutra 1 i ze one another. Vul pi an's conclusions 
were that curare is not a direct anti dote for strychnine and neither 
is strychnine a direct antidote for curare; and that in the case of 
tetanus, curare would merely add another hazard in the presence of a 
prognosis which was already grave (Vulpian, 1857). 
Claude Bernard performed his classical experiments on frogs in 1854 
and pub 1 i shed these reports in 1857. He observed that motor nerves 
alone were affected and that the sensory nerves were spared (Bernard, 
1857) (fig. 2). 
Fig. 2 Frog, experiment C. Bernard 
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In 1932 West reported on the hypodermic administration of curare to 
thirty patients, seventeen of whom he described, including patients 
suffering from epilepsy, rigidity due to pyramidal lesions and 
Parkinsonism. The first paediatric patient to receive curare was 
described: 11 a girl aged 13 with a right-sided hemiplegic 
contraction, lasting since birth. Spontaneous athetoid movements 
occurred from time to time and the arm would take up unusual postures 
sometimes for a considerable period. Curare in increasing doses up to 
12 milligrammes was given and it was not until this dosage was reached 
that symptoms were noticed. The injection was followed by nystagmus on 
fixing the eyes to the left. There was no di pl opi a. The child was a 
1 i ttl e giddy on walking, the arm hung a 1 most flaccid by the side. 
Passive flexion encountered no resistance, extension was met by a 
temporary clasp knife rigidity, which gave way to allow full extension 
in a manner which had not been possible before. The first dose in this 
case produced a marked fall in blood pressure from 120/60 (pulse 74) 
to 94/60 (pulse 60) and this hypotension remained for over twelve 
hours. Four days later the blood pressure was 122/64 and the pulse 84. 
Cardiac extrasystoles occurred when the pulse-rate was at its lowest 
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Hest considered his communi cation to be, from the therapeutic point of 
view, both preliminary and tentative. Yet he forecasted a place for 
curare in therapeutics and pleaded for more research and purification 
of curare (West, 1932). In 1938 West reported that curarine caused a 
bronchial spasm, resembling that caused by histamine. As an antidote 
for bronchial spasm, bradycardia and hypotension adrenalin was used 
(West, 1938). 
In 1940 Bennett published a report on how traumatic complications in 
convulsive shock therapy were reduced by intramuscular or intravenous 
injections of an infusion or an alcoholic extract derived from crude 
curare. He used this technique on a large number of spastic paralytic 
children. As antidote he advised epinephrine and neostigmine (Bennett, 
1940). 
The introduction of curare into clinical anaesthesia was reported 
by Griffith and Johnson in 1942 with their publication: "The use of 
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curare in general anesthesia". Intocostrin, a water soluble extract of 
unauthenticated curare, was given intravenously in a dosage of 10-20 
mg of the active curare per 20 lbs (9 kg) of body weight. It produced 
a rapid and "complete" muscular relaxation within one minute, 
gradually disappearing over 10-15 minutes. None of the 25 patients 
showed any evidence of serious depressing effects on res pi ration. 
pulse or blood pressure. A second injection on the same day required a 
smaller dose. All patients underwent inhalation anaesthesia with 
neostigmine used as an antidote for the curare. They warned against 
its somewhat fleeting action and stressed that in no sense could 
Intocostri n be considered as an anaesthetic agent. It should be used 
only by experienced anaesthetists in well-equipped operating rooms 
(Griffith, Johnson, 1942). 
In the Netherlands F. Van Nouhuys from the Red Cross Hospital in The 
Hague first used curare in anaesthesia in 1946 (Van Nouhuys, 1947). He 
warned against the differences in potency between the two available 
curares: Intocostrin and Myostatin. He stated that curare is non-
narcotic and ad vi sed the use of reduced dosages in children. In 
October 1946 Myostatin was also introduced in the 'Wilhelmina 
Gasthui s' in Amsterdam by Mrs. Vermeul en-Cranch. According to Mauve 
(1948) by November 1947 175 curare-anaesthetic procedures had taken 
place, with the youngest patient being 16 years old. 
Almost immediately after the introduction of curare into anaesthesia 
practice by Griffith, the use of the drug was extended to the 
paediatric age group; such was the case in the Sophia Children's 
Hospital (fig. 3). In adult anaesthesia these advancements contributed 
greatly to extending surgical possibilities. For example the muscle 
relaxation achieved with curare assisted the surgical course, 
especially in the case of laparotomies, thoracotomies and orthopaedic 
procedures. This of course was also true for paediatric surgery, which 
was still a very young surgical discipline. Despite the fact that 
Socrates (470-399 B.C.) had asked his fellow Athenians: "Why do you 
gather riches and care so little for the children to whom you will 
have to leave it all?", Hippocrates (460-377 B.C.) had pointed out 
special features of diseases in childhood and Celsus (25 B.C.- 50 
A.D.) had stated that children should be treated entirely differently 
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Fig. 3 Operating Room, Sophia Children's Hospital, circa 1970 
from adults, it took almost 2000 years before physicians began to take 
interest in neonates, infants and children. The cause for this long 
delay may lie with Soranus (98-117 A.D.) who relegated the diseases of 
infants and children to the area of midwifery. In the meantime it were 
the barber- surgeons, a 1 though not accepted as physicians, who took 
care of the infants and children. Although not very capable in 
treating and curing, some described congenital anomalies and produced 
beautiful drawings (Van Meekeren, 1611-1666, reprint 1979). 
The English physician George Armstrong was a rare exception. In 1769 
he opened his Dispensary for Children (mainly for the poor) in 
Holborn (London). Although he was met with abuse by his colleagues, 
his entire life was devoted to the care of sick children. Nobody took 
up his cause when he died, until in 1802 when the first Hospital for 
Sick Children was opened in Paris. Armstrong has left us a treatise on 
paediatrics. 
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During the Nineteenth Century many more children's hospi ta 1 s wer, 
founded and, at last, surgery became acccepted as a medical 
profession; with appointments of the first paediatric surgeons. 
Closely integrated with the developments in surgery, paediatrics, 
anaesthesia, biochemistry, radiology and pathology, paediatric surgery 
thrived in the Twentieth Century. 
The morta 1 i ty rate for paediatric surgery early in the Nineteenth 
Century remained as high as 40-60 %. Improvement was achieved with the 
development of modern anaesthesia and the discovery of antisepsis by 
Lister in 1867. In 1953 Snyder and colleagues reviewed 66 cases of 
sudden cardiac arrest in children occurring in the operating room. As 
probable causes they mentioned anoxia and vagovagal reflex. This was a 
major step forward si nee many sudden deaths under anaesthesia had 
previously been attributed to "status thymico-lymphaticus" until 
Professor Henry Cohen stated in 1939 that this was a meaningless 
term. 
Snyder and colleagues noticed an alarming increase in the incidence 
of cardiac arrest between 1948-1953 and considered it to be a problem 
of anaesthesia. Simple open-drop technique had changed to the use of 
the anaesthetic machine with more dead space and res pi ra tory 
resistance (Snyder et al ., 1953). In the period between 1947 and 1956 
the frequency of cardiac arrest associated with anaesthesia in infants 
was 1 in 600, in children 1 in 1700 and in adults 1 in 2500. Hypoxia 
and ether overdose were reported to be among the common causes (Rackow 
et al ., 1961). Graff and coworkers stated that mortality from 
anaesthesia was five times greater in the paediatric age group 
compared with adults and that respiratory problems were implicated in 
83% of these deaths(Graff et al ., 1964). 
Nowadays it is known that the respiratory physiology of the newborn 
differs from that of the adult. With an overall metabolism per 
kilogram bodyweight almost twice that of an adult and a lung surface 
area per ~logram approximately the same, a baby has less reserve of 
lung surface area for gas exchange to meet any increased metabolic 
demand. The closing volume in the neonatal lung is larger than the 
functional residual capacity, so airway closure occurs within normal 
ti da 1 res pi ration. 
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Hypoxia in neonates may also result in additional effects not seen 
in older children. Severe metabolic acidosis is common due to the 
neonates increased capacity for anaerobic metabolism. Cerebra 1 and 
pulmonary haemorrhage, severe hyperkalaemia and hypoglycaemia may also 
be associated with hypoxia. To worsen the situation, hypoxia and 
acidosis cause pulmonary constriction and, in the first few days of 
1 ife, may result in the ci rcul a ti on reverting to the transi tiona 1 
circulation of the newborn with right to left shunting through the 
foramen ova 1 e and ductus arteriosus. This in turn 1 eads to further 
hypoxia. 
Controlled ventilation ensures that adequate alveolar ventilation 
takes place and some positive end-expiratory pressure (PEEP) helps to 
maintain an adequate residual volume. Moreover, in neonates the 
minimum alveolar concentration (MAC) for halogenated agents is higher 
than the concentration that remains free from cardiovascular and 
ventilatory side effects. Thus, from an anaesthesia point of view, it 
is of great advantage to paralyse and ventilate the suckling. 
Nevertheless, it is still frequently stated that the use of relaxant 
drugs in neonates is contraindicated because they are unnecessary. 
Jackson Rees is, however, correct in pointing out that control of 
respiration is extremely desirable in infants (Jackson Rees, 1950). 
Improvement in the paediatric endotracheal tube by ~1agill (1936) and 
the invention of the T-piece by Ayre in 1937 brought comparative peace 
to the operating theatre during operations for hare-lips and cleft 
palates, formerly the scene of many sanguinary battles (Ayre, 1937). 
The insight of Smith (1953) on how to prevent tracheitis in children 
following endotracheal anaesthesia reduced the number of undesirable 
side effects due to intubation. 
The use of relaxants became well-established, with advantages 
including: improved surgical conditions, non-flammability and the 
possibility to operate on a motionless patient during a shallower 
stage of anaesthesia. As the safety factor associated with anaesthetic 
agents diminishes with use in neonates, relaxation of the patient with 
d-tubocurarine therefore became a part of the famous Liverpool 
technique of anaesthesia in neonates and infants. 
Originally only oxygen was added to curare for infant surgery, but 
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when Smith, after testing curare on himself, reported the complete 
absence of cerebral effects of the drug, meaning that patients were 
completely conscious when fully paralyzed, this technique was 
abandoned (Smith, 1947). Nitrous oxide was added and, together with 
oxygen and d-tubocurarine, formed the principal agent for 
anaesthetizing all infants and children whilst being ventilated 
(Jackson Rees 1950, 1958, 1960, 1965). 
Research on muscle relaxants in adult and paediatric patients 
proceeded. Other relaxants were found and tested. The de pol ari zing 
neuromuscular blocking drug succinylcholine became popular, especially 
si nee Stead reported that infants had an increased to l era nee to this 
drug (Stead 1955). In 1952 L.A. Boer{~, head of the Department of 
Anaesthesia in Lei den, introduced Ce l ocuri n (succi nyl choline iodide) 
in the Netherlands. He recommended dosages of 0.1-1.0 mg/kg i .v. as a 
bolus or in a drip, dependent on whether spontaneous respiration, or 
even a respiratory arrest was required. Indications for use of 
Celocurin were: endotracheal intubation, cholangio-, arteria- and 
angiography, electroshock and operations requiring relaxation. 
Of the 48 patients (age range 8-81 years) rece1 v1 ng Cel ocuri n no 
difficulties were reported (Boer~, 1952). Subsequent disclosure that 
succinylcholine may cause severe bradycardia (Leigh et al., 1957), 
dual block (Churchill-Davidson et al., 1960) and prolonged apnea 
( Churchi 11-Davi dson, 1959) reduced its popularity. Many anaestheti sts 
returned to the use of the more predictable nondepolarizing 
neuromuscular blocking drugs. Baird and Reid (1967) published the 
first report on the use of pancuronium in anaesthetized patients. 
Thereafter, the use of many other relaxants, i ncl udi ng vecuroni um 
bromide, followed. 
In 1955 Stead pointed out that the response of infants to the 
nondepolarizing muscle relaxant d-tubocurarine is different from that 
of adul~s. Infants showed an increased sensitivity. Although his 
"evidence" was based on experience with only two infants, the basic 
observation has been upheld by subsequent work and initiated an 
important line of investigations (Stead, 1955). 
Churchill-Daviason (1963) measured the electromyographic response of 
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five neonates to decamethonium, a depolarizing neuromuscular blocking 
agent, neostigmine sulphate and edrophoni urn, both anticholinesterase 
drugs, antagonizing the effect of nondepolarizing muscle relaxants. He 
concluded that the neuromuscular transmission in the first few weeks 
of life differed from that found in adult patients and that the 
characteristics of the block obtained after decamethonium strongly 
resembled many of the features seen in patients with myasthenia 
gravis. 
Research into the development of the neuromuscular system was also 
in progress (Buller, 1966; Koeningsberger et al., 1973). More articles 
were published on neuromuscular blockade in neonates, infants and 
children (Long, Bachman, 1967; Walts, Dillon, 1969; Zsigmond, Downs, 
1971; Yamamoto et al., 1972; Nightingale, Bush, 1973; Goudsouzian, 
1980; Cook, 1981). Despite all these efforts controversies remained as 
to whether children were more (Stead, 1955; Lim et al ., 1964; Long and 
Bachman, 1967), equal (Goudsouzian et al., 1974) or less (Goudsouzian 
et al., 1975) susceptible to the blocking action of the neuromucular 
blocking agents. 
Difficulties are found in comparing results because of differences 
in the methods of measuring blockade (by force or by electromyogra-
phy), differences in stimulation, muscles to be measured, calculated 
doses (by kg bodyweight or m2 body surface) anaesthesia techniques 
(use of halogenated agents or not), body temperature, arterial PCOz 
and others. Last but not least, the actual drug studied also varies 
among the many publications. 
Nowadays, clinical anaesthesia is inconceivable without the use of 
muscle relaxants. Nevertheless the problems associated with the 
pharmacodynamics of the drugs in neonates, infants and children still 
needs further investigation. Working daily with the young, we decided 
to undertake another study on the effects of a modern nondepolarizing 
relax ant drug, vecuroni urn bromide, in the various paediatric age 
groups. In order to compare the results we strived to keep as many 
parameters as possible constant, using a uniform anaesthesia 
technique, avoiding drugs known to influence neuromusc~ar 
transmission, and studying patients without metabolic or neuromuscular 
diseases. 
17 
Hopefully this study wi 11 contribute to the understanding of the 
pharmacodynamics of vecuronium in these different age groups. 
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II NEUROMUSCULAR BLOCKING AGENTS IN THE PAEDIATRIC AGE GROUP 
Since the first use of neuromuscular blocking agents in children 
controversies, including the correct dosage required, have remained. 
Hany objections were based on the contradictions involved. Neonates, 
infants and children, depending on the respecbve outcomes of studies, 
were considered to be more, equal or less sensitive to these drugs 
than adults. The diverse conclusions reached by various authors depend 
to a great extent on the methodology used for investigation of the 
compounds. Various ways were used to define the effect: apnea, ability 
to control respiration, ease of endotracheal intubation and more 
increasingly sophisticated monitoring techniques. 
QUANTITATIVE MONITORING OF THE NEUROMUSCULAR FUNCTION 
Evoked electromyography (EMG), the technique chosen for our study, 
was first used by Harvey and Masland in 1941. They stimulated the 
ulnar nerve electrically and recorded the electrical response of the 
abductor digiti minimi muscles. Another possible technique is the 
recording of the mechanical response by mechnomyography (MMG). With 
MHG the clinically important muscle contraction (excitation-contrac-
tion coupling etc.) is also included in the measurement, whereas with 
EMG only the neuro-muscular transmission part is measured. The best 
approach for an in vivo nerve-muscle preparation is by stimulating the 
ulnar nerve and recording the force of adduction of the thumb by the 
adductor pollicis brevis muscle. The advantage of using evoked 
responses is that the cooperation of the patient is not necessary and 
the stimulus is standardized. Thus this method is very suitable for 
patients under anaesthesia. In paediatrics, mechanomyography is com-
plicated by the bulkiness of the equipment and thus electromyography 
is the technique of choice. 
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The action potential and contraction of a single muscle fibre is of 
an "all or nothing" type. Increase in contraction force or action 
potential amplitude of a muscle is due to an increase in the number of 
parti ci pa ti ng contracting muscle fibres (recruitment). For measuring 
EMG or MMG supramaximal stimulation is always used. All possible 
fibres must be excited to exclude interference by recruitment. 
Another important factor is the type of stimulation. The stimuli 
should be 0.1-0.2 msec in duration. If the duration of a stimulus 
exceeds 0.2 msec the refractory period is exceeded and a second action 
potential may occur. The ideal electrical impulse is a square wave 
rectangular (Epstein et al .• 1969). The stimulus frequency has a major 
influence on the obtained results. especially when the frequency is 
high (Ali, Savarese, 1980). The most commonly used stimulustypes are: 
- single twitch at slow rates (0.1-0.2 Hz) 
- train-of-four stimulation (2 Hz for 2 seconds) 
- tetanic stimulation (50 Hz for 5 seconds) 
Single twitch rates are useful whenever there is a control response, 
taken before administration of the muscle relaxant. By comparing the 
percentage of change in twitch tension or EMG amplitude ( deflection) 
due to the relaxant, a percentage value can be obtained, indicating 
the degree of paralysis. Relatively high degrees of acetylcholine 
receptor occupation are detected by this method. 
Depression of twitch response can only be observed if more than 75% of 
the postsynaptic receptors are blocked. When 90% or more are occupied, 
a state of complete paralysis exists (Waud, Waud, 1972). A higher dose 
of relaxant is required to depress the twitch height when the 
stimulus frequency decreases. At high frequencies there is depletion 
of acetylcholine and consequent fading in response. This is more 
pronounced and occurs at a lower frequency in relation to the age of 
the children. 
The train-of-four consists of four supramaximal stimuli applied at a 
frequency of 2 Hz. There is fading in the responses when a nondepola-
rizing relaxant drug is administered. The ratio of the amplitude of 
the fourth twitch to the first is used for assessment of superficial 
neuromuscular blockade. The fourth response in the train is eliminated 
at approximately 75% depression of the first twitch. The third and 
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fourth twitches are abolished at 80% suppression of the first twitch 
while. in addition. the second twitch becomes undetectable at about 
90% block of the first twitch. Thus for clinical purposes merely 
counting the number of twitches in the train-of-four response makes it 
possible to quantify the extent of a more pronounced blockade (Ali. 
1985). A rate of 2 Hz is rapid enough to produce depletion of the 
immediately available stores of acetylcholine. yet slow enough to 
prevent transmitter release and synthesis facilitation. Four stimuli 
were chosen because the fourth response is maximally depressed during 
partial nondepolarizing neuromuscular blockade. Thereafter the twitch 
height levels off. 
There is a linear relationship between single twitch and train-of-
four values. Goudsouzian and colleagues found this correlation for 
vecuronium in children (2-17 years of age) during recovery to be very 
good (Goudsouzian et al .• 1983a). Correlations between EMG single 
twitch and train-of-four are varying. Differences are found between 
onset and recovery of blockade and between different blocking agents 
(Calvey et al .• 1983, Goudsouzian et al .• 1983b). 
In children anaesthetized with halothane without administration of 
muscle relaxants the components of the train-of-four are practically 
equal in size. thus the train-of-four ratio is 100%. In infants less 
than one month of age the train-of-four ratio is 95% (Goudsouzian. 
1980) and in premature infants 83% due to spontaneous fading in 
response (Goudsouzian et al .• 1981). This difference in baseline 
causes difficulties in comparing the effects of neuromuscular blocking 
agents using this technique in different age groups. i ncl udi ng 
neonates. 
Tetanic stimulation increases mobilization and enhances synthesis of 
acetylcholine to a limited degree. If the duration of the stimulus is 
too long or if the frequency is too high. spontaneous fade occurs. 
Fade is more marked in neonates and especially in premature infants 
(Churchill-Davidson. Wise. 1963; Koenigsberger et al .• 1973). 
VARIOUS FACTORS 
Previous studies reported no statistically significant difference in 
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the time to 95% twitch depression with needle or surface electrodes 
(Stiffel et al., 1980; Capan et al., 1981). For proper interpretation 
of mechanomyography, attention should be paid to the capacity of the 
force transducer, the relation of the transducer to the direction of 
movement of the muscle studied, the initial muscle tension and 
avoidance of the contribution of direct muscle response to the 
measurement. Electromyography is di ffi cult and expensive for everyday 
clinical monitoring of neuromuscular function, but more suitable 
apparatus have now been developed for routine clinical use (Carter et 
al., 1986; Harper et al., 1986; Pugh et al., 1984). The principal 
techniques for examining the EMG are measurement of the EMG peak 
height and the surface area by integration of the EMG response. Both 
approaches of the analysis have been published (Ali et al ., 1971; Lam, 
Cass, 1981). The correlation between the two methods is extremely 
close (r=0.976) (Pugh et al., 1984). Evoked electromyographic and 
mechanical responses of the adductor pollicis generally show a good 
correlation (Crul et al., 1983). A difference however can be observed. 
This difference is drug-specific and is more pronounced during onset 
of blockade than during its antagonism by neostigmine (Harper et al ., 
1986). 
FACTORS INFLUENCING THE MECHANISM OF ACTION OF NONDEPOLARIZING MUSCLE 
RELAXANTS 
Suxamethoniumchloride, a depolarizing relaxant, is frequently used to 
facilitate intubation of the trachea whereafter a nondepolarizing 
agent is administered to relax the patient during surgery. Prior 
admi ni strati on of suxamethoni urn enhances the neuromuscular blocking 
effect of non-depolarizing blocking agents (Walts, Dillon, 1969; Katz, 
1971; Buzello et al., 1983). It augments both the degree and duration 
of the blockade induced by vecuronium (Krieg et al., 1981; 
D'Hollander, 1983). 
Hypothermia influences the effect of neuromuscular blocking drugs. 
Studies show a species-dependent difference. For example, the conduc-
tion velocity in the nerve axon during hypothermia is increased in the 
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squid axon (Hodgkin, Katz, 1949) and is unchanged in the frog sarto-
rius pre para ti on (Katz, Mil edi , 1965) . The sensi ti vi ty of the 
postjuncti onal receptors to transmitter is decreased, unchanged or 
increased in different species (Zink, Bose, 1974; Thornton et al., 
1976). The response of directly stimulated muscle during hypothermia 
is also variable in different species. The mechanism of the effect of 
hypothermia on the interaction of muscle relaxants with the neuromus-
cular function is complex. 
In cats Miller et al. (1975) found hypothermia to augment a d-tubo-
curarine blockade. Ham et al. (1981) studied humans during hypother-
mia. They reported that pharmacoki netic variables were not si gni fi-
cantly affected. No difference was found in the steady-state serum 
concentration that resulted in 50% paralysis during hypo- or normo-
thermia. They concluded that the sensi ti vi ty of the neuromuscular 
junction of d-tubocurarine is not affected by hypothermia. In a few 
patients there was a marked delay in onset time. Remarkable was that 
spontaneous recovery of neuromuscular function, measured by EMG, was 
similar, but measured by MMG was prolonged in the hypothermic group. 
Buzello and collegagues (1985) studied alcuronium, d-tubocurarine, 
pancuronium and vecuronium during (hypothermic) cardiopulmonary bypass 
using EMG and MMG. Hypothermic cardiopulmonary bypass attenuated 
alcuronium, d-tubocurarine and pancuronium neuromuscular blockade. 
Vecuronium neuromuscular blockade was enhanced, vecuronium was no 
longer a shorter-acting agent than pancuroni urn under these circum-
stances. The difference in response may be explained by a direct 
effect of hypothermia at the neuromuscular junction, rather than by 
pharmacoki netic factors related to bypass. The EMG is more sensitive 
than is the MMG in reflecting the effect of changing body temperature 
on neuromuscular transmission ( Buzell o et a l., 1987). One concludes 
that, in order to compare pharmacodynamic data in different age 
groups, the body temperature must be kept normal and constant. 
Hypercarbia and hypocarbia have been studied in relation to pancuro-
nium-induced neuromuscular blockade. Wirtavuori and colleagues showed 
recovery after neostigmine to be slower in hypoventilated patients 
with MMG. This effect, however, was not seen using EMG amplitude 
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(Wirtavuori et al., 1982). This finding was interpreted as evidence 
for the direct depressant effects of carbon dioxide on contractility. 
Lee and Katz (1980) claimed the EMG amplitude to be a better indicator 
of actual neuromuscular blockade than measurement of twitch tension in 
this situation. Gencarelli and coworkers (1983) studied pancuronium 
and vecuronium using MMG. Hypocarbia and hypercarbia, induced before a 
single dose of either drug was given, had little effect on pancuronium 
and vecuroni urn dose-response rel a ti onshi ps and recovery rates 
(recovery from 75-25% block). Acutely induced hypocarbia caused an 
increase and hypercarbia a decrease in control twitch tension. During 
partial pancuronium or vecuronium neuromuscular blockade, hypocarbia 
induced an increase in twitch tension. Acute hypercarbi a caused a 
si gni fi cant decrease in twitch tension during a partial vecuroni urn 
blockade.The observed effect was much larger than the decrease 
observed for pancuroni urn. The conclusion must be that the neuromus-
cular junction is not the main side where hypercarbi a effects evoked 
twitch contraction. 
Metabolic changes in acid-base balance 
Most workers found that metabolic acidosis or alkalosis affect the 
action of d-tubocurari ne in the same way as res pi ra tory acidosis or 
alkalosis. But the neuromuscular block produced by gallamine was 
affected the opposite way, being antagonized by res pi ra tory acidosis 
and potentiated by resp-iratory alkalosis. These effects are usually 
attributed to changes in the binding of gallamine to plasma proteins. 
(Katz et al., 1963; Crul-Sluyter and Crul, 1974; Miller and Roderick, 
1978). 
In vivo studies in the cat showed a significant antagonism of 
vecuronium by metabolic alkalosis, whereas metabolic acidosis caused a 
potentiation of the M~1G quantitated blockade (Funk et al., 1980). 
Antibiotics and neuromuscular function 
Anti bi oti cs may enhance the neuromuscular blocking properties of 
muscle relaxants. However there are many differences in quality and 
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quantity. That the effect can be of serious clinical significance was 
first reported by Pridgen in 1956. Antibiotics were classified 
according to Weinstein, rather than by the incompletely understood 
mechanism by which they produce neuromuscular block (Sokoll, Gergis, 
1981). 
1. Drugs inhibiting synthesis of bacterial cell wall. 
In terms of producing a neuromuscular blockade, antibiotics of this 
group are the safest. Penicillin blockade, if it occurs, may be 
reversed by calcium, but is unaffected by neostigmine. This suggests 
that the probable site of action is at the prejunctional nerve 
terminal. 
2. Agents affecting the permeability of the cell membrane. 
Polymycins and colistin are examples of this group. They cause a 
blockade of complex origin, predominantly postsynaptic, which is not 
reversed by ca 1 ci urn or neostigmine. 4-Ami nopyri dine wi 11 reverse the 
block (Lee, de Silva, 1979). 
3. Agents inhibiting protein synthesis. 
There are two groups of such agents. The first and most important 
group for enhancing neuromuscular blockade includes the aminoglycosi-
des (streptomycin, neomycin, kanamycin, gentamycin) and the 
lincosamides (lincomycin, clindamycin). They show a wide range of 
activities. Most of these drugs have combined actions on both nerve 
terminal and the cholinergic receptor, can be reasonably well reversed 
by calcium and partially reversed by neostigmine (Albiero et al., 
1978; Singh et al., 1982; Booij et al., 1978). The second group 
consists of tetracycl in and oxytetracycl in. Both drugs possess weak 
and clinically insignificant neuromuscular blocking properties. The 
mode of action in producing neuromuscular block has not been complete-
ly elucidated. The blockade is usually reversible by calcium, but not 
by neostigmine (Singh et al., 1978; Ibsen, Urist, 1962; Bowen, 
McMullan, 1975; Pittinger, Adamson, 1972). 
Hcindewar studied an interaction between vecuroni urn and some anti-
microbial agents in the cat, using MMG (Mcindewar, Marshall, 1981). A 
streptomycin-benzyl peni ci 11 in mixture causes a si gni fi cant potentia-
tion of the neuromuscular blocking activity of vecuronium. An appa-
rently specific potentiating interaction was observed between vecuro-
25 
nium and metronidazole. Krieg et al. (1980) studied neomycin, genta-
mycin and clindamycin in combination with vecuronium. The dose-
response curve of vecuronium shifted to the left but in clinical 
dosages the time-course of the effect of a bolus dose of vecuronium 
was unaltered. 
Volatile anaesthetic agents 
Many studies have demonstrated an increase in the magnitude and 
duration of nondepolarizing neuromuscular blockade by volatile 
anaesthetic agents. Confusion concerning potentiation does not exist. 
Most investigators used MMG (Rupp et al., 1984; Waud, 1979), but 
EMG produced the same results (Stirt et al ., 1983; Lee et al., 1984). 
Differences between species do not exist in this regard. Human and 
animal studies, both in vitro and in vivo, all show a dose-dependent 
potentiation in the magnitude of b 1 ockade of many different nondepo-
larizing . neuromuscular agents caused by many different volatile 
anaesthetics. In addition, Stanski et al., (1979) reported that 
halothane does not alter the pharmacokinetics of d-tubocurarine. 
Vecuroni urn was investigated by Foldes et al. (1980), Nagashima et 
al. (1981), Duncalf et al., (1983), Lee et al., (1983, 1984) and Rupp 
et al ., (1984). All authors found potentiation, a shift to the left of 
the dose-response curve. But Rupp et al. (1984) found potentiation of 
vecuronium to be less dependent on the concentration of volatile 
agents than that of pancuronium. Enflurane potentiates most, followed 
by isoflurane and then halothane. The recovery rate (75-25% blockade) 
is also prolonged (Lee et al., 1983). Enflurane without a relaxant 
drug also has effect on neuromuscular transmission: the twitch 
response decreases, fade and posttetani c faci 1 ita ti on occur. These 
effects cannot be antagonised by neostigmine (Lebowitz et al., 1970). 
Several mechanisms have been proposed by which volatile anaesthetic 
agents produce relaxation and augment the neuromuscular blockade from 
muscle relaxants. However the exact mechanism has not yet been 
elucidated. One theory is that normally the equilibrium between normal 
resting and desensitized states of the receptors favors the former, 
making receptors available for acetylcholine binding and causing 
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neuromuscular transmission. This equil i bri urn is a 1 tered by vo 1 a tile 
anaesthetics, which encourage formation of the desensitized state and 
reduce the number of available resting receptors, thus weakening 
neuromuscular transmission and anhancing the action of nondepolarizing 
agents (Standaert, 1984). 
Concerning a 11 the factors i nfl uenci ng the neuromuscular junction 
and neuromuscular blocking agents, it is not surprising that compari-
son of the results from various studies is difficult (Miller, 1986). 
Moreover many more drugs may interfere with nondepolarizing relaxants, 
some very important, some clinically irrelevant, as reported by Katz 
( 1985). In experimental settings it is easy to avoid such drugs, but 
not clinically. For example it is difficult to anaesthetize very young 
children without the use of volatile agents when they cannot be com-
pletely relaxed, such being the case when dose-response curves or re-
covery are studied. Most neonates requiring surgery, have some metabo-
1 i c disturbances or receive anti bi oti cs. Thus to avoid differences 
when comparing the effect of neuromuscular b 1 ocki ng agents in diffe-
rent age groups, it is essential to exclude such patients from the 
studies. 
Comparison of different studies may also be hampered by the use of 
different neuromuscular blocking drugs. In some of these drugs pre-
junctional effects may be of more importance than in others (Blaber, 
1973; Bowman, 1980a; Stanec, Baker, 1984). At slow rates of motor 
nerve stimulation it is easier to detect the "static" postjunctional 
effects. However, if one studies the "dynamics" of synaptic transmis-
sion using near-physiological rates of stimulation (20-50Hz), failure 
of the various prejunctional functions is revealed (Galindo, 1972). 
Pancuronium possesses prominent postjunctional effects but more 
recent studies indicate that it has significant prejunctional actions 
(Su et al., 1979), a long-established fact for d-tubocurarine 
( L i 11 eheil , Naess, 1961) . Torda and Kil oh ( 1982) found in the toad 
sartorius preparation that ORG NC 45 ( vecuroni urn) reduces the main 
quantal content of the end-plate potential as well blocking post-
junctional receptors. Another consideration is the difference found in 
the relation between single twitch and train-of-four ratio during 
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onset and recovery of the blockade. The fade of the trains is much 
more marked during recovery than during onset in a vecuronium blockade 
(Bowman. 1980a). 
Comparing the effects of muscle relaxants in children of different 
age groups gives additional problems to the ones already described .. 
For the past 30 years investigators have attempted to ascertain 
whether the responses of the newborn infant to nondepolarizing muscle 
relaxants do indeed differ from those in the adult, and to define the 
possible causes for these differences. 
Throughout childhood there is physical and biochemical maturation of 
the neuromuscular junction. change in the properties of skeletal 
muscle and an increase in the relative amount of muscle as a 
proportion of body weight. But at the same time the apparent volume of 
distribution, and possibly the metabolism, the redistribution and the 
clearance of relaxants also change. Since all these factors can 
influence pharmacodynamics and pharmacokinetics it is not surprising 
that the neonate's responses to relaxants have not yet been defini-
tively clarified. 
MATURATION OF THE NEUROMUSCULAR SYSTEM 
At 7.5 weeks gestational age the human foetus starts to move. These 
first movements may not be initiated by a nerve action but by activity 
of the muscle itself (Joppich. Schulte, 1968). 
At 11 weeks motor nerves reach the muscle cells of the biceps muscle 
and at 12 weeks the muscles of fingers and toes. At 26-28 weeks 
gestational age the motor nerve ends differentiate into the later 
motor end-plates. The structural and functional development of the 
neuromuscular system is incomplete at birth (Cook, 1981). The human 
myoneural junction has by then developed postsynaptic infoldings and 
some degree of ramification. Only by 2 years of age has the myoneural 
junction complete ramification and segmentation as in the adult 
(Juntunen~ Teravainen, 1972). 
The differentiation of muscle fibres proceeds along the histogenetic 
course: from myoblasts via myotubes to mature muscle fibres. The 
criteria used for differentiation vary slightly from author to author. 
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Si nee deve 1 opment is a continuous process, intermediate forms may be 
observed (Buller, 1966). The myotubes progress to the stage of mature 
muscle fibres with the migration of the centrally placed nuclei to the 
margins of the fibre. The pale axial cytoplasm disappears, its place 
being taken by newly formed myofibrils which ultimately fill the 
mature cell. So the tubular appearance of the myotubes is lost. This 
transition from myotube to rna ture muscle fibre occurs in the 1 a tter 
part of intra-uterine life and in the first few weeks after birth 
(Buller, 1966). The proximal muscles are the first to develop. There 
is a subsequent progressive proximo-distal differentiation, the 
muscles of the hand and foot being the last to form. The muscles of 
the hand differentiate slightly earlier than those of the leg. 
As early as in 1678 Lorenzini divided skeletal muscles of warm 
blooded beings into two groups: red and white. In humans such a marked 
difference does not exist (Joppich, Schulte, 1968). In man all of the 
skeletal muscle consists of a mixture of two basic fibre types, type I 
and II. The relative proportions vary from muscle to muscle. Type I 
fibres have a high con centra ti on of the oxidative enzymes concerned 
with aerobic metabolism. They belong to motor units which, when 
activated, develop a relatively slow and sustained, tonic contraction. 
Type II fibres have a high concentration of myosin ATPase and of 
glycolytic enzymes such as phosphorylase. These fibres, when 
stimulated, generate a more rapid and less sustained, phasic 
contraction. Type II fibres can be subdivided in two types, IIA and 
liB and in the immature muscle also in IIC on basis of their myosin 
ATPase activity at different pH's and levels of oxidative enzyme 
activity, Type IIA is fast oxidative glycolytic and type liB is fast 
glycolytic. Type IIC fibres show a myofibrillar ATPase staining still 
present at pH 4.3. 
A clear subdivision into the two histochemical fibre types cannot be 
made with certainty until between the 18th and 20th weeks of 
gestation. Prior to the 19th week there is a uniform population of 
fibres in the vastus lateralis with the staining characteristics of 
type IIC fibres. During the last three months of pregnancy their 
number decreases progressively and type IIA and liB fibres appear in 
the pattern of mature human muscle. From weeks 20-26 only a small 
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proportion of the fibres show the characteristics of type I. After 26 
weeks there is a progressive increase in numbers of type I fibres and 
from 30 weeks gestation to full term the muscles show a chequerboard 
pattern similar to that of mature adult muscles with approximately 
equal numbers of type I and type II fibres (Mastaglia, 1981). 
With maturation of muscle fibres some slow-contracting muscle is 
progressively converted to fast-contracting muscle with a concomittant 
change in the force-velocity relationship. However, in both the dia-
phragm and the intercostal muscles in infants an increase in the 
percentage of slow muscle fibres occurs in the first month of life; 
thus conversion of muscle types can go in both directions (Keens et 
a l . , 1978) . There appears to be considerable variation in the exact 
timing of this change, not only from species to species but also from 
one muscle to another in the same animal (Buller, 1966). Even in 
adults, where all muscles are mature, it is not possible to apply 
observations made in one muscle to other muscle groups (Weber, 1984). 
Studies have been made on different muscle groups by various 
investigators and many differences between onset time and sensitivity 
to neuromuscular blocking agents have been observed (Wymore, Eisele, 
1978; Lebrault et al., 1985; Donati et al., 1986; Pathak et al., 
1986). The major physiologic differences found between muscle types 
correspond, to a large extent, to the relative ratios of fast to slow 
muscle fibres found in the muscles (Weber, Muravchick, 1986). Most 
muscles are mixtures of these fibres, generally ranging from 30-90% 
slow fibres (Johnson et al., 1973). Even in the hand considerable 
differences are found. The human adductor pollicis muscle contains 
approximately 80% slow fibres and the abductor digiti minimi about 52% 
slow fibres. 
Neuromuscular transmission depends on four main factors: 
-the quantity of acetylcholine released by each motor nerve inpulse 
- the sensitivity of the post-junctional cholinoceptor to 
acetylcholine 
- the excitation threshold of the muscle fibre membrane adjacent to 
the end-plate region 
- the level of activity of the acetylcholinesterase present at the 
junction 
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The first factor may be subdivided into the number of acetylcholine 
quanta released by each nerve impulse and the amount of acetylcholine 
contained in each quantum. Recording of the amplitude of spontaneous 
miniature end-plate potentials provides information about the depola-
rizing action of a single quantum on the post-junctional membrane. 
End-plate potentials obtained in response to electrical stimuli are 
used to estimate the average quantum content (Hubbard et al., 1969). 
Normally motor nerve endings release more acetylcholine than is 
required to ensure action potential formation in skeletal muscle. This 
is termed the safety factor. The size of the safety factor depends on 
the depolarisation produced by each quantum of acetylcholine, the 
number of quanta released by each nerve impulse and the difference 
between the resting membrane potential and the excitation threshold 
potential of the muscle fibre. 
In rats of 110 days old the miniature end-plate potential was found 
to be half of that found in rats of 30 days old. The number of quanta 
released by each nerve impulse was 2.5-3 times as much in rats of 110 
days old as in rats of 30 days old. There was no difference in resting 
membrane potential. The resulting calculated safety factor in rats of 
30 days old was 70-80% that of 110 days old rats (Kelly, Roberts, 
1977). If extrapolation from rat experiments to human is valid, these 
results suggest that infants will have a lower safety factor than 
adults and will therefore be more sensitive to nondepolarizing 
relaxants. 
The development of acetylcholine receptors on muscle fibres has been 
studied extensively. In the cultured and embryo muscle fibres most of 
the acetylcholine receptors are diffusely distributed and freely 
mobile within the cell membrane. Some focal hot spots have an 
increased sensitivity. The establishment of nerve-muscle contact 
causes the immobilization of a dense cluster of receptors in the 
postjuntional membrane at the neuromuscular junction. The extra 
junctional receptor formation is depressed and the extrajunctional 
sensitivity to acetylcholine decreased (Bowman, 1980). In the human 
upper arm the period from the i ni ti a l contact between axons and 
myotubes through the appearance of secondary postjunctional folds 
occurs between weeks 10 and 16 of gestation. 
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Acetylcholinesterase activity first appears as a diffuse stain in 
myotubes at embryonic stages. As the neuromuscular junction forms, the 
activity of acetylcholinesterase is localized to the synaptic gutter, 
the intercellular space between axon and Schwann cell and the nuclear 
envelope and tubular reticulum of both myotubes and Schwann cells 
(Carry, Morita, 1984). 
In neonates EMG and MMG can both be used to study muscles. In 1963 
Churchill-Davidson and Wise using Ef•1G showed that at twitch rates of 
0.25 Hz neuromuscular transmission is well maintained in neonates, but 
a tetanic rate of 50 Hz is poorly maintained. Ten years later 
Koeni gsberger and coworkers ( 1973) made the same observation. Using 
EMG they found fading tetanus and post-tetanic exhaustion more marked 
in premature than in full-term infants. The latter having less 
myoneural reserve than older children and adults. Their data suggest 
that the infant neuromuscular junction may not be fully developed at 
birth and that rna tura ti on of the neuromuscular junction continues 
during neonatal development. Goudsouzian (1980) demonstrated a 
difference in neuromuscular transmission between neonates 1 ess than 
one month of age and infants and children aged between two months and 
nine years. He used EMG, but no blocking agents. All patients received 
halothane. Train-of-four ratio values increased significantly with 
age. Post-tetanic facilitation after 50 Hz stimulation was more marked 
in the group aged two months and older. There was also a significant 
negative corre 1 a ti on between age and contraction time. He cone 1 uded 
that rna tura ti on of neuromuscular transmission occurred in the first 
two months after birth. Crumrine and Yodlowski (1981) showed a 
measurable age-dependent difference between the myoneural function of 
infants less than 12 weeks old and that of older children and adults. 
They used the frequency- sweep e 1 ectromyogram ( FS-EMG) response 
pattern. By the age of 12 weeks the FS-EtvlG became adult-1 ike. The 
diminished FS-EMG response in the high-frequency region of the younger 
infants indicates that these infants are unable to maintain a tetanic 
contracture because of fa i 1 ure in neuromuscular transmission. This 
provokes speculations that the margin of safety in the newborn is less 
than that in more mature individuals. 
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MATURATION OF THE KIDNEYS 
The fetal kidneys produce diluted urine from as early as the third 
month of intrauterine life, although the excretory and regulatory 
requirements of the fetus are satisfactorily carried out by the 
p 1 acen ta. At birth the kidneys must fully take up their ro 1 e of 
excretion of the nitrogeneous end-products of metabolism and play a 
part in stabilizing the volume, osmotic pressure and chemical 
composition of extracellular fluid. Overall renal function is immature 
in the newborn. The glomeruli are smaller than in the adult, but their 
filtration surface in relation to body weight is similar. In relation 
to the extracellular fluid volume however, the filtration is less. The 
tubules are not fully grown and may not extend into the medulla. 
During the first few days after birth the function of the kidneys 
improves rapidly and there is a spurt of growth. This is partly caused 
by the increase in the tota 1 cardiac output the kidneys receive. The 
stimulus of birth causes the kidneys of the very premature infant to 
hypertrophy by developing new nephrons and increasing the glomerular 
surface area. The kidneys have full complement of nephrons by 36 weeks 
gestation, but there is a considerable heterogeneity in the extent of 
maturation of individual nephrons. The immaturity includes scant vas-
cularity, short tubulus, low tubular volume and hypocellular glomeruli 
with small surface area. After birth the cuboidal glomerular epithe-
lium is replaced by specialized epithelial cells. The tubules ,engthen 
and absorption and secretion increase while the tubular volume attains 
maturity earlier than the glomeruli. 
Glomerular filtration rates (GFR) decrease in the first 24-48 hours, 
but rise again by the 7th-10th day. In the first month of life the 
mean GFR is about 25-33% of that expected for size as related to adult 
values. Between 3 and 6 months of age it is 50%, rising to 75% between 
6 and 12 months of age. About the middle of the second year of 1 i fe 
the GFR becomes 100% of the expected figure of size. The concentration 
capacity at birth is also immature. The infant's kidney can concen-
trate urine to a maximum of about 700-800 mmol/kg whereas the older 
child and· adult can a chi eve 1200-1400 mmol /kg (Houston, Oetl i ker, 
1981; Smith and Smith, 1982; Hatch, Sumner, 1986). 
33 
The ha lf-1 ife of a drug, excreted unchanged through the kidneys is 
often inversely correlated to the gestational age. This is most 
probably connected to the inverse correlation between glomerular 
filtration rate and gestational age. After the first 3-5 days of life, 
especially in full term babies, usually a significant reduction in 
plasma half-life occurs of those drugs, excreted mainly through the 
kidneys. The capacity of neonates to metabol i se drugs shows a 1 arge 
interindividual variability. 
Renal elimination accounts for 40-50% of the clearance of 
d- tubocurarine and pancuroni urn, thus rena 1 failure has a proto und 
effect on their pharmacokinetics. The clearance is decreased so the 
terminal elimination half-life is increased. With small doses the 
effect is minor, but with larger paralyzing doses the recovery rate of 
paralysis is delayed. Approximately 12% of d-tubocurarine is normally 
eliminated unchanged into the bile, but if the renal elimination is 
impaired this percentage increases. For pancuroni urn the si tua ti on in 
renal failure is more adverse as its active metabolites are also 
normally excreted by the kidney (Stanski, Watkins, 1982). Atracurium 
is spontaneously broken down by Hofmann elimination to inactive 
breakdown products. Vecuronium elimination is not dependant on renal 
clearance. Both drugs are sui table muscle relaxants for patients 
without rena 1 function. Thus considering the immature rena 1 function 
of the neonate, d-tubocurarine and pancuronium should be avoided 
whereas atracurium and vecuronium can safely be used. 
NATURATION OF THE LIVER 
Before birth most of the functions of the liver are performed by the 
placenta or by the maternal liver, but at birth the liver must take on 
its role in body homeostasis. The weight of the liver is 4% of total 
body weight in the newborn, compared to 2% in the adult. 
At birth there is great diversity in the maturation of enzyme systems. 
Some aspects of 1 i ver function such as detoxi cation and carbohydrate 
metabolism are poorly developed, with resultant inability to metaboli-
ze such compounds as bilirubin and chloramphenicol for several weeks 
after birth. The 0-dealkylation of pancuronium and vecuronium is less 
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affected. Other functions such as synthesis of albumin and coagulation 
factors are relatively normal. Because of this impaired metabolism al-
most all of the drugs studied in the neonatal period have a prolonged 
elimination half-life. Pathologic conditions such as hypoxemia, 
cardiac failure and poor nutritional status may further depress the 
activity of rnetabol i zing enzymes in the newborn. The abi 1 i ty to meta-
bolize drugs can be enhanced by maternal exposure to enzyme inducers, 
such as smoking and phenobarbitone ( Sereni et a 1., 1981). Ma tura ti on 
of liver enzyme systems occurs rapidly. Usually by 3 months of age the 
enzyme systems function at adult level. The initial phase of reduced 
metabolic clearance in the neonate is followed by a phase of marked 
increase in metabolic activity in the infant and child. The period in 
which this occurs is highly variable and unpredictable, but comes 
after improvement of the clearance of unchanged drugs through the 
kidneys. The faster recovery in chi 1 dren, compared to adults, from 
twitch paralysis by some relaxant drugs can be explained on the basis 
of enhanced hepatic excretion of metabolic clearance. This has been 
demonstrated for pancuronium and vecuronium, muscle relaxants with a 
high liver clearance. For d-tubocurarine, excreted unmetabolized by 
the kidney, this was not confirmed (Martyn, 1986). 
CHANGES IN BODY COMPOSITION 
The total body water content of the newborn is proportionately 
higher than the adult, due principally to a relative excess of extra-
cellular fluid. Neonates at term consist for 82% of the fat-free 
weight of water and adults for 72%. Extracellular water in prerr?.ture 
infants is about 50% of the body weight, decreasing to 45% at term, 
30% at t\~O months of age, 23% at adolescence and 16% in adults. 
The intracellular fluid increases from 30% in prematures to 35% of the 
body weight at birth, to 40% at the age of one year and to 47% at 7-16 
years. 
The percentage of fat in the body falls considerably between 1 and 5 
years of age. Thereafter it increases, more in females than in males. 
8ut in adipose tissue it increases from 45% at birth to 60% at 6 
months of age. Skeletal muscle, in relation to body composition, is 
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quantitatively the most important soft tissue. It accounts for 25% of 
the body weight of the preterm and full term baby and 40% of the 
weight of an adult (Widdowson, 1981). 
The difference in body composition and metabolism of immature tis-
sues must be considered as the physiological basis for the differences 
in drug disposition in newborn and premature infants compared with 
older children and adults. The distribution volume of a drug is mainly 
determined by the amount of body water and the degree of binding to 
plasma-proteins, the size of fat depots and tissue binding. In neona-
tes the total body water and the extracellular water as a percentage 
of body weight are high. Fat depots are relatively small and the total 
amount of muscle tissue is low. All these factors can influence the 
relative volume of distribution (RVD). In the majority of the cases 
the RVD is found to be greater in neonates. The primary cause of this 
is the relatively greater extracellular water volume and possibly some 
difference in the plasma protein binding of the drugs. The molecular 
mechanisms underlying reduced plasma protein binding in newborn 
infants are not yet entirely understood. But the concentration in 
those tissues for which the drug is active still determines the 
therapeutic effectiveness (Sereni et al., 1981). 
Nondepolarizing muscle relaxants are highly ionized, regardless of 
pH, extremely water soluble and unable to penetrate cell membranes 
rapidly. Distribution of these drugs is limited to extracellular water 
(Stanski, Watkins, 1982). Since the percentage of bodyweight of 
extracellular water is higher in neonates the final drug concentration 
is lower when the given dose of relaxant is based on body weight. The 
di stri buti on volume is increased in neonates as demonstrated for 
d-tubocurarine (Fisher et al., 1982). 
CLINICAL EXPERIENCES WITH NONDEPOLARIZING RELAXANTS IN PAEDIATRIC 
ANAESTHESIA 
In 1950 G. Jackson Rees stated in his article "Anaesthesia in the 
newborn", that "the time has come to consider the problem of anaes-
thetizing the newborns in relation to their peculiar physiology". He 
proposed that control of respiration is extremely desirable in 
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infants, but the use of relaxant drugs in neonatal anaesthesia was 
contra- indicated, being unnecessary (Jackson Rees, 1950). In the 
years to follow however, muscle relaxants became a part of anaesthetic 
technique for operations on newborn infants. Stead wrote in 1955 that 
in L i verpoo 1 over three hundred neona ta 1 surgery cases have been 
performed using re 1 axants. He used an ingenious device to measure 
res pi ration pressure using suxamethoni urn chloride and d-tubocurari ne 
chloride as relaxants. He concluded that resistance of the neonate to 
the depolarizing agent suxamethonium chloride is clearly shown, but 
that neonates are extremely sensitive to 
agent d- tubocurarine c h 1 ori de. In this 
myasthenic patient (Stead, 1955). 
the competitive blocking 
regard they resemble a 
Sa 1 ani tre described the res pi ra tory comp 1 i cations associ a ted with 
the use of muscle relaxants in young infants. He reviewed 220 infants 
less than 13 weeks of age (Salanitre, 1961). He found that 27% of the 
infants given a muscle relaxant had postoperative respiratory 
depression, compared to 12% in those who did not receive any relaxant. 
This increase in respiratory depression rate was partly due to the 
hypothermia that occurred more often if the patient was re 1 axed and 
partly as a result of overdose of the relaxant. Although 
Churchill-Davidson and Hise found in the first few weeks of life a 
neonate to resemble a myasthenic patient, they failed to show an 
increased sensitivity of the hypothenar muscles to d-tubocurarine 
'under cyclopropane anaesthesia using EMG (Churchill-Davidson, Wise, 
1963). 
Lim used a dose of d-tubocurarine to produca respiratory depression 
without apnea in 134 children from 5 weeks to 16 years of age and 
found that children under 1 year of age required about one-fourth of 
the dose per kg compared to children over 12 years of age (Lim et al., 
1964). Long urged caution in the use of d-tubocurarine in infants and 
children. He stated that provided small initial doses are used, body 
coo 1 i ng is avoided, no deep ha 1 othane anaesthesia is given and as a 
routine drugs are used for reversal, no special hazards exist with the 
use of d-tubocurarine in halothane anaesthesia, measuring the 
hypothenar EMG response (Long, Bachman, 1967). Two years later Walts 
and Di 11 on found newborns to be more sensitive to d-tubocurari ne than 
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adults, when administered on the basis of surface area using 
halothane and force of thumb adduction (Walts, Dillon, 1969). 
In the 1970's confusion had not lessened. Bennett and colleagues 
studied pancuronium and d-tubocurarine in many children including 
neonates. They seldom used a nerve stimulator, thus seldom measured 
EMG or MMG. Clinical signs were their guideline for determining onset 
time and recovery. They found that the onset time of pancuroni urn 
increases with age and the duration of action with increasing doses. A 
special observation was made, when they reported the potency ratio of 
pancuronium, compared to d-tubocurarine, to range from 9:1 at birth to 
6:1 at one month of age (Bennett et al ., 1975). Bennett and colleagues 
also studied the effect of tubocurarine in 50 neonates (1-28 days) 
including 27 born prematurely. They found that tubocurarine, given in 
a bolus can be used safely. The recommended dose doubles from 250 
meg/kg at birth to 500 meg/kg at 28 days. This dose must be reduced in 
the event of prematurity, acidosis or hypothermia, or when certain 
antibiotics or inhalation anaesthetic agents are present in the 
tissues. Reversal can be obtained after one hour (Bennett et al., 
1976). 
Lippman and Rogoff failed to show a benefit for calculating doses on 
basis of surface area rather than on the basis of weight in a study of 
100 children (1-10 years of age). They used a nerve stimulator on the 
ulnar nerve but estimated the muscle response in an unclear way. The 
children were divided in 5 age groups regarding onset time, but 
results are practically uniform. The duration of action is not given 
for different age groups (Lippman, Rogoff, 1974). 
Goudsouzi an and coworkers were the first to attempt to draw an 
accurate dose-response curve of pancuronium in the paediatric age 
group. They studied the force of the thumb resulting from single 
stimulations of the ulnar nerve. Incremental doses were given to 17 
patients (5 weeks to 7 years old) including 3 infants from 5, 7 and 7 
weeks old, all under halothane anaesthesia. The 3 small infants did 
not show a different dose-response curve when compared with older 
children, but dosage based on surface area is excessive for infants. 
No division in age groups was made. Comparing their study with others 
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they came to the conclusion that children may require more pancuronium 
than adults to reach the same degree of muscle relaxation. Recovery 
rate however is the same as in adults (Goudsouzian et al., 1974). One 
year later another study from Goudsouzian and colleagues was 
published. This time on d-tubocurarine in 44 children of 4 different 
age groups (1 day-7 years old), using basically the same technique as 
in 1974. The cumulative dose-response curves showed a tendency of the 
infant of 1 day old to require higher doses of d-tubocurarine to 
achieve the same amount of twitch inhibition as their older confreres. 
The same age group showed the widest deviation of response. However a 
sta ti sti call y significant difference was not found in dose-response 
using single twitches nor in recovery time using train-of-four in the 
various groups of infants and children in this study. However infants 
and children seem to recover somewhat faster than adults from similar 
levels of neuromuscular depression produced by d-tubocurarine. In the 
same study a high correlation (r=0.93) is shown between single twitch 
and train-of-four (Goudsouzian et al ., 1975). 
Antagonism of blockade 
For the reversal of residual neuromuscular blockade cholinesterase 
drugs are used. Inadequate reversal is likely to occur if it is 
attempted within 30 minutes of the time of administration of the 
relaxant or if potent anaesthetic agents are used as part of the 
anaesthetic technique (Bennet et al ., 1971). 
P HARMACOK IN ETI CS AND PHARMACODYNAMICS OF d-TUBOCURARINE AND 
PANCURONIUM 
d-Tubocurarine (fig. 4) 
A combined pharmacoki netic and pharmacodynamic study in 9 children 
(1 month-9 years old) showed that plasma levels of d-tubocurarine at 
steady state 50% depression of twitch height [CPss(50)] are not dif-
ferent between children and adults. Neither are there differences in 
the central and steady state volumes of distribution and distribution 
half-lives between children and adults. However the clearance is 
greater and the elimination half-life correspondingly shorter in 
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Fig. 4 d-Tubocurarine 
children. Anaesthesia was induced and maintained with halothane. 
Paralysis was assessed by quantitating the e l ectromyographi c twitch 
height in reponse to supramaximal stimulation of the ulnar nerve 
(O'Keeffe et al ., 1979). 
In 1982 an article on pharmacokinetics and pharmacodynamics of 
d-tubocurarine in infants, children and adults was published by Fisher 
and colleagues 31 patients were studied, divided in neonates (0-2 
months old), infants (2-12 months old), children (1-12 years old) and 
adults. All patients received 0.58 MAC halothane. Single supramaximal 
stimuli were given to the ulnar nerve and the resulting EMG of the 
adductor pollicis muscle was measured. d-Tubocurarine concentrations 
were measured and fitted in a two-compartment, first-order pharmaco-
kinetic model. The plasma d-tubocurarine concentration at which 50% 
depression of EMG twitch height occurred [CPss(5o)J was found 
significantly lower in neonates and infants than in children and 
adults. The steady state distribution volume (Vdssl in neonates is 
greater and the elimination half-life longer than in children and 
adults. The authors concluded to an increased sensi ti vi ty to 
d-tubocurarine as determined by CPss(50)· However because of the 
larger Vdss in younger patients, dose size does not differ with age. 
In addition, because of the longer elimination half-life in neonates, 
second and subsequent doses are required at less frequent intervals 
(Fisher et al., 1982). 
Matteo and coworkers studied the distribution and urinary excretion 
of d-tubucurari ne over a period of 24 hours and in some of the 35 
patients they also measured the EMG in hopes to reconcile conflicting 
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reports. The EMG was recorded after single stimuli of the ulnar nerve 
during halothane anaesthesia. Patients were divided in neonates (0-1 
month old), infants (1-12 months old), children (1-4 years old) and 
adults. No differences were found between the initial volume of 
distribution. Both neonates and infants exhibit decreased plasma 
clearance and a prolonged half-life of elimination. The neonate's 24 
hours urinary excretion is significantly less than the adult volume. 
The plasma concentration - EMG response between 20 to 80% paralysis 
did not show a difference between the age groups except for 2 of the 
7 measured neonates. They were found to be less sensitive to d-tubocu-
rarine and were placed in a subgroup. The recovery did not show a 
difference between the various age groups (Matteo et al., 1984). 
Pancuronium (fig. 5) 
An electromyographic study using train-of-four on pancuronium in 14 
children (6 months-12 years old) under light halothane anaesthesia 
(less than 0.5%) revealed no differences in duration and degree of 
blockade from pancuronium between an age group of 0.5-6 years old and 
an age group 7-12 years old. Train-of-four ratio is found to be more 
sensitive than single twitch as an index of the recovery of transmis-
sion (Esener, 1983). 
H C-C-0 3 II 
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Fig. 5 Pancuronium bromide 
Comparative studies on d-tubocurarine and pancuronium 
The relation between train-of-four ratio and single twitch after 
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d-tubocurari ne and after pancuroni urn was further studied by Robbins 
and colleagues in 40 patients, aged from 1 day-12 months. 
The force of contraction of the adductor pollicis muscle after stimu-
lation of the ulnar nerve was measured under narcotic anaesthesia. The 
decrease in force of contraction in response to a single stimulus com-
pared with control, was indicative of the classical postjunctional 
site of action. A fade of response to train-of-four stimulation occur-
red. They found more prejunctional effects during the recovery phase 
than during onset for d-tubocurarine and pancuronium, the prejunctio-
nal effects being more marked with d-tubocurarine. But prejunctional 
neuromuscular activity is less marked in infants than in adults 
(Robbins et al ., 1984). 
Goudsouzian and coworkers in a comparative study between d-tubocura-
rine and pancuronium found, that the duration of action is shorter in 
children (4 months-10 years of age) than in adults. They used the 
force of thumb adduction after train-of-four stimulation of the ulnar 
nerve under narcotic anaesthesia ( Goudsouzi an et a 1 . , 1981). In 1984 
the same group compared i denti ca 1 muscle relaxants in 56 chi 1 dren 
(1-15 years old). They determined the cumulative dose-response curves 
under narcotic anaesthesia with single sti mula ti on of the thumb and 
recorded the force of thumb adduction. They found that children have a 
tendency to require more relaxant and to recover more quickly than 
adults. But a statistical significance was not proven (Goudsouzian et 
al.,l984). 
PHARMACOKINETICS AND PHARMACODYNAMICS OF ATRACURIUr~ AND VECURONIUM 
In the 1980's the nondepolarizing muscle relaxants atracurium and 
vecuronium were introduced in clinical anaesthesia. Considering the 
sensitivity of the neonate and the prolonged recovery phase of 
relaxation in the newborn, these relaxants of intermediate duration 
are very welcome. 
Atracuri urn (fig. 6) 
The pharmacokinetics of a tracuri urn in infants ( 1-8 months of age) 
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Fig. 6 Atracurium besylate 
and children (2-10 years of age) have been studied by Brandom and 
coworkers during i sofl urane anaesthesia. They found a si gni fi cant 
difference in volume of distribution (ml/kg) and clearance of 
a tracuri urn ( ml /kg/min) . 
Infants show a larger volume of distribution and a higher clearance. 
Plasma elimination half-lives (T 1/2 alpha and T 1/2 beta) and the 
clearance expressed on a basis of body surface (mlfm2fmin) tend to be 
shorter in infants as compared to children, but these trends did not 
reach statistical significance (Brandom et al ., 1986). 
Some investigators measured the infusion rate, necessary to obtain a 
steady state blockade of a certain percentage, reflecting the rate of 
removal. Brandom and colleagues adjusted the infusion rate of 
atracurium to maintain neuromuscular block within the range of 89-99% 
using EMG and first twitch to control in children of 2-10 years. 
Ouring fentanyl anaesthesia the infusion rate was 558 mcg/kg/h (1356C 
mcgfm2/h), during 0.8% halothane anaesthesia 408 mcg/kg/h (10500 
mcgfm2fh), and during 1% isoflurane anaesthesia 354 mcg/kg/h (8820 
mcg/m2/h) (Brandom et al ., 1985). 
Goudsouzi an studied atracuri urn in children aged 1-10 years, main-
taining a blockade of 90-99% of control, using MMG and first twitch 
compared to control. During morphine anaesthesia the infusion rate was 
558 mcg/kg/h, during 1% halothane 498 mcg/kg/h and with 2% enflurane 
294 mcg/kg/h {Goudsouzian et al., 1986a). In another report from 
Meretoja and Ka 11 i ( 1986a), no ha 1 ogena ted anaesthetic agents were 
used. Two groups were studied with fentanyl anaesthesia, using EMG and 
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train-of-four stimulation. Newborn infants to 3 months of age required 
a continous infusion of 400 mcg/kg/h and children over 5 kg to 16 
years of age 530 meg/kg/h. 
Gramstad and Lilleaasen (1985) studied adults. using fentanyl anaes-
thesia, MMG and first twitch compared to control. For atracurium the 
infusion rate to maintain 90% blockade had to be set at 383 meg/kg/h. 
Eagar and collegues (1984) studied atracurium in patients from 42-77 
years old under halothane anaesthesia (0.25-0.5%), using MMG and first 
twitch. They found a requirement of 366 mcg/kg/h to maintain a 
blockade of 90-100%. D'Hollander and coworkers (1982) found 2791 
mcgfm2fh and Noeldge and colleagues (1984) 87 meg/kg/h. both using MMG 
and fentanyl anaesthesia. Brandom and colleagues (1985) compared their 
results with the results of D' Hollander and coworkers (1982). who 
studied three adult age groups. They concluded that when infusion 
requirements are expressed on a surface area basis, the rate of 
removal of atracuri um is independent on age from 2-85 years of age. 
The clinical effect of atracurium in 270 neonates was observed by 
Nightingale. He advised a lower dose of atracurium (300 meg/kg instead 
of 500 meg/kg) in neonates less than 48 hours old, especially when 
body temperature is low (less than 36°C). The reason for this being an 
increased recovery time (Nightingale, 1986). Cook found older children 
(24 boys, median age 13 years) to be somewhat resistant to atracurium 
compared to adults. He measured the thenar EMG with train-of-four 
stimulation of the ulnar nerve during halothane anaesthesia. He also 
warned that when using a cumulative dose-response curve inste,ad of a 
single dose method one overestimates the ED95 by 55%. The ED95 
estimated from the single dose response curve is 154 meg/kg and the 
ED5o is 101 meg/kg (Cook et al .• 1982). In 1986 Cook and coworkers 
found age-related differences using the same method, between 45 
infants (age 1-6 months) and 45 children (age 2-10 years) in ED5o and 
ED95 for atracurium but not for pancuronium. Unfortunately numbers are 
not given (Cook et al .• 1986). 
Meretoja and Kalli studied the effects of a bolus dose of 0.4 mg/kg 
atracurium under balanced anaesthesia. measuring single twitch and 
train-of-four ratio quantified by EMG of the hypothenar muscles. They 
found the control value of the train-of-four ratio to be 99 ± 1% in 
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patients under 5 kg body weight as compared to 100% in heavier 
patients. The maximal blockade in 65% of the patients under 10 kg was 
more than 98% whereas this was only 32% in patients over 10 kg. The 
recovery rate (75-25% EMG depression) is longer in patients under 5 kg 
than in patients from 5-10 kg and longer in patients from 5-10 kg than 
in heavier patients (14.2, 11.6 and 10.2 min respectively) (Meretoja, 
Kalli, 1986b). 
Another com pari son of a tracuri um-i nduced neuromuscular blockade in 
neonates, infants and children was made by Meakin and colleagues under 
balanced anaesthesia, measuring force of thumb adduction after single 
twitch stimulation. Neonates (1-28 days old) appeared to be more 
sensitive to atracurium than infants (1 month-1 year old) and children 
(1-5 years old). The ED5o's are respectively 79 mcg/kg,115 meg/kg and 
137 meg/kg. The ED95's are respectively 109 meg/kg, 155 meg/kg and 191 
meg/kg. However the recovery of the first twitch to 10% of the control 
is significantly faster after a bolus of 0.5 mg/kg atracurium in 
neonates (22.1 min) than in infants (29.7 min) and children ( 28.6 
min) (Meakin et al., 1987). 
Brandom and coworkers performed many studies on atracurium in 
infants from 1 month old to children of 10 years of age. Infants (1-6 
months old), children (2-10 years old) and adolescents (11-16 years 
old) were given atracurium under halothane (1% end tidal) anaesthesia. 
The ulnar nerve was stimulated by train-of-four and the resulting EMG 
of the,thumb was recorded. The percentage block was calculated by 
comparing the first twitch to the control measurement. Dose-response 
curves were calculated from single doses. ED5o and ED95 were 
calculated on a base of weight and of body surface area. For neonates 
the ED5o's are 85 meg/kg and 1600 mcgfm2, for children 132 meg/kg and 
3266 mcgfm2 and for adolescents 101 meg/kg and 3338 mcgfm2. The ED95's 
are for neonates 156 meg/kg and 3330 mcg/m2, for children 260 meg/kg 
and 6628 mcgfm2 and for adolescents 157 meg/kg and 6302 mcgfm2. The 
dose-response curve for children is shifted significantly to the 
right, compared to infants and adolescents, when calculated on a 
weight base. However when calculations were made on surface area basis 
the dose-response curves for children and adolescents were i denti cal 
and the curve for infants shifted significantly to the left of the 
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other two groups. Brandom and coworkers also found halothane to 
potentiate the effect of atracurium but no significant difference was 
found. Recovery time after equal multiples of the ED95 was signifi-
cantly shorter in infants than in older children and adolescents, but 
the recovery time from 25 to 95% of control does not differ between 
the three age groups (Brandom et al., 1984). 
A comparison of the pharmacodynamic data on atracurium was made by 
Goudsouzian studying infants (4 weeks-1 year old), children (1-10 
years old) and adolescents (11-17 years old) under halothane anaesthe-
sia. Train-of-four stimulation of the ulnar nerve was used and the 
resulting force of thumb adduction measured. The percentage of 
blockade was the first twitch related to the control. The time from 
injection to maximal effect and the recovery time were not different 
between the age groups. However a significantly faster recovery time 
was observed in chi 1 dren as compared to adults, both groups during 
narcotic anaesthesia. Cumulative dose-response curves with ha 1 othane 
anaesthesia were made for each age group. The calculated ED50 and EDg 5 
did not show a difference when expressed in mg/kg, (ED5o 0.10, 0.11 
and 0.12 mg/kg and EDg5 0.17, 0.17 and 0.18 mg/kg). But calculated on 
surface area infants are more sensitive to a tracuri urn than children 
and children more than adolescents: respectively EDg5 3.3, 4.7 and 6.4 
mgfm2 (Goudsouzian et al ., 1985). A significant difference in ED5o and 
ED95 of infants of 1-3 months of age and infants of 3-12 months of age 
was found by Meistelman and colleagues. But they found this difference 
both when calculated on weight and on surface area basis. The calcu-
lated ED5o's are respectively 86 meg/kg equals 1408 mcgJm2 and 131 
meg/kg equals 2664 mcgfm2. The ED95's are 175 meg/kg equals 3281 
mcgfm2 and 205 meg/kg equals 4544 mcgfm2. The technique used by this 
group was stimulation of the ulnar nerve and measuring the EMG of the 
thenar muscles under halothane anaesthesia (1 MAC) (Meistelman et al., 
1986a) . 
Vecuronium 
As vecuronium is the subject of our study, it is discussed 
separately in Chapter III. The last part of that chapter describes the 
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pharmacokinetics and pharmacodynamics of vecuronium in the paediatric 
age group. 
GENERAL CONCLUSIONS 
Comparing studies on non-depolarizing neuromuscular blocking agents 
in adults is difficult (Miller, 1986). Factors such as stimulation 
technique and choice of monitoring technique of the evoked responses 
of the muscle are important. Major artefacts can be caused by 
interactions with other drugs used, including anaesthetics and 
depolarizing blocking agents (Viby-Mogensen, 1985), by changes in 
body temperature and by acid-base balance. All this is also of concern 
in studies on the paediatric age group. In this group however growth 
and development are also major factors. Body composition changes and 
liver, kidney and neuromuscular junction become mature. It is thus not 
surprising that much confusion exists. There is little measure of 
agreement between various authors, neither in their ways of ex peri-
mental procedure, nor in their conclusions. Between the ages of 0 and 
1 year it is not possible to compare various studies as no two age 
groups for children are identical and anaesthesia and monitoring 
technique also vary. For vecuronium only two studies have been 
performed in infants, both using halothane anaesthesia but with 
different monitoring techniques. 
Si nee little is known about the pharmacodynamics of vecuroni urn in 
the paediatric age group, especially in infants, and since vecuronium 
is a modern relaxant of intermediate duration best meeting the concept 
of an ideal muscle relaxant (Booij, Crul, 1983), the aim of this 
study is to investigate pharmacodynamics in neonates, infants and 
children. Using a uniform procedure and keeping all variables as 
normal as possible within each age group enables a comparison to be 
made between neonates, infants and children. 
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III VECURONIUM BROMIDE 
The first to describe the synthesis and pharmacology of vecuronium 
bromide, which was then still known as ORG NC 45, were Buckett, Hewett 
and Savage (1973). In search of the ideal neuromuscular blocking drug 
(Karis, Gissen, 1971; Savarese, Kitz, 1973) research was being done on 
derivates of steroidal relaxants and the bulky choline esters. Thus 
the pavulon analogues were investigated by (in alphabetical order) 
Agoston, Booij, Bowman, Crul, Marshall, Miller and their coworkers. 
All these compounds have in common the androstane skeleton (fig. 7). 
Fig. 7 Androstane skeleton 
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Fig. 8 Vecuronium bromide 
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The investigated compounds differ only in the side chains at the C3, 
C17 and the two N-atoms (Booij, 1982). Org NC 45 (fig. 8) is the most 
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potent of the monoquaternary compounds. Its structural formula is: 
1[(2 beta, 3 alpha, 5 alpha, 16 beta, 17 beta) - 3, 17 - bi s 
(acetyl oxy) - 2 - ( 1-pi peri di nyl) - androstan - 16 - YL] - 1 -
methylpiperidinium bromide. 
Marshall (1968) found the block produced by ORG NC 45 to be of a 
nondepolarizing type. With the knowledge available at that time no 
advantages were seen with this compound. Moreover the compound is 
unstable in aqueous solution (Savage et al ., 1980) and further 
investigations were temporarily abandoned. 
The importance of cardiovascular side effects of neuromuscular 
blocking drugs gradually became more apparent. Accordingly a series of 
analogues of pancuronium was tested again (Savage et al., 1980). ORG 
NC 45 again became a subject of research. Animal investigations began 
in 1975 (Durant et a 1., 1979a; ~1arsha 11 et a 1., 1980), fo 11 owed by the 
first human studies (Crul, Booij, 1980; Baird, Herd, 1980; Buzello et 
al ., 1980; Krieg, Crul et al., 1980; VanderVeen, Becini, 1980). 
Animal studies confirmed that the block caused by ORG NC 45 is of a 
nondepolarizing nature and mainly postjunctional in origin (Durant, 
et al., 1979a; Torda, Ki loh, 1982). Vecuroni urn is a highly potent 
neuromuscular blocking drug in the same order as pancuronium (Kerr, 
Baird, 1982; Agoston et al., 1980; Gramstad et al., 1982). The 
approximate relative potency of vecuronium in adult man based on cal-
culations of the effective vecuronium dose resulting in a maximal 
blockade of 50% (ED5ol as compared with d-tubocurarine is 5.6. For 
pancuronium this is 4.7 and for atracurium 1.1. The ED5o of vecuronium 
varies in different studies on adults between 15 and 31 meg/kg as an 
i .v. bolus dose. The ED9o lies between 23 and 43 meg/kg and the ED95 
between 38 and 56 meg/kg. A major cause of the differences found here 
is the variation in techniques (Fahey et al., 1981a; Gramstad et al., 
1983; Robertson et al., 1983a; Engbaek et al., 1984; O'Hara,1985). 
Vecuroni urn has a suffi ci entl y high a ffi ni ty for the recognition sites 
of the postjunctional receptors for it to block transmission before 
any ion channel occlusion is produced (Baird et al ., 1982). The latter 
is difficult to reverse with anticholinesterase agents. Vecuronium 
blocks the postulated prejunctional receptors and so produces the 
various fade phenomena on train-of-four and tetanic stimulation 
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(Bowman, Webb, 1976; Bowman, 1980a; Bowman et a l., 1983; Williams et 
al., 1980; Baker, 1986). 
Pharmacodynami call y vecuroni urn is a nondepol ari zing neuromuscular 
blocking agent with an intermediate duration of action. The clinical 
duration of muscle relaxation (time between injection and return of 
twitch to 25% of control) is 21-38 minutes in adults (Agoston, 1983; 
Foldes et al ., 1983; Bencini, Newton, 1984; Engbaek et al ., 1984). 
A dose of vecuronium producing 90% depression of contraction results 
a total duration of action (time from injection to 90% recovery) of 
ca. 25 minutes in adults. A bolus dose varying from 20-100 meg/kg has 
a duration of action of 20-45 minutes ( Agoston et a l . , 1980; Fahey 
et al., 198la; Ali et al., 1983; Booij, Crul, 1983; Engbaek et al., 
1983a). Thus vecuronium in adults has the shortest duration of action 
of all clinically used nondepolarizing muscle relaxants. In adults the 
recovery rate (time from 25-75% recovery) after a bolus injection of 
vecuronium 43-120 meg/kg varies from 6.8-15 minutes (Agoston et al., 
1980; Ali et a l . , 1983; Robertson et a l . , 1983a; Benci ni , Newton, 
1984). 
Using comparable doses of relaxant the recovery rate of vecuroni urn 
is the shortest (10 minutes) directly followed by atracurium (11 
minutes). The recovery rate of pancuronium is long (32 minutes) and of 
d-tubocurarine the longest (59 minutes). 
Unfortunately the rapid onset time (time from injection to maximal 
effect) of suxamethonium chloride, a depolarizing relaxant drug is 
unequalled by any nondepolarizing relaxant. But the onset times of 
vecuroni urn and a tracuri urn are shorter than the onset times of most 
other nondepolarizing relaxant drugs. After a bolus injection of 
vecuronium 73-200 meg/kg onset times varying from 2.2-6.7 minutes were 
measured in adults (Agoston et al., 1980; Fahey et al., 198la; 
Gramstad et al., 1982a; Foldes et al., 1983; Bencini, Newton, 1984; 
Engbaek et al., 1984). Little or no cumulation at all is found for 
vecuronium (Agoston et al., 1980; Fahey et al., 198la; Buzello, 
Noldge, 1982; Ali et al., 1983; Engbaek et al., 1984; Fisher, Rosen, 
1986). The reversibility of vecuronium by cholinesterase inhibitors 
equals that of pancuronium (Baird et al., 1982; Gencarelli, ~1iller, 
1982; Caldwell et al., 1986). 
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Animal studies show a lack of cardioselective atropine-like action 
of vecuronium at clinical blocking doses and at doses many times 
greater (Durant et al., 1979a; Booij et al., 1980a; Marshall et al ., 
1980; Marshall et al., 1983). In human studies vecuronium is without 
sympathetic stimulation, ganglion blockade or vagolytic effect (Crul, 
Booij, 1980; Krieg et al., 1980a; Agoston et al., 1980; Fahey et al., 
1981a; Barnes et al., 1982; Engbaek et al., 1983b; Morris et al., 
1983; Cozanitis, 1986). Histamine release as seen with the use of 
d-tubocurarine and to a lesser extent with atracurium is of no concern 
in the case of vecuronium (Booij et al., 1980b; Basta et al., 1983; 
Robertson et al., 1983b). 
Pharmacokinetically vecuronium is characterised by a rapid total 
plasma clearance (Sohn et al., 1982; Cronnelly et al., 1983). This is 
mainly due to substantial hepatic uptake shortly after intravenous 
injection. For a large proportion no further redistribution takes 
place. Total biliary elimination amounts to 40-50% of the administered 
dose. Renal excretion is 20-30% of the injected vecuronium, the 
majority of which is eliminated within 12 hours after administration. 
Most of the vecuronium is unchanged (Bencini et al., 1983). Less than 
one-fifth of the total amount is eliminated as the 3-0H metabolite and 
this breakdown product has not been detected in plasma (Sohn et al., 
1982). Plasma concentration data do not show statistically significant 
differences in patients with no renal function compared to healthy 
subjects. In these renal failure patients, even with extremely large 
doses, the duration of neuromuscular blockade was unchanged (Fahey 
et al., 1981b; Bencini et al., 1983; Meistelman et al., 1983; Hunter 
et al., 1984). This is in contrast to the duration of blockade in 
patients with liver disease, who displayed a prolonged effect of 
vecuronium, which is more pronounced in cirrhosis than with 
cholestasis (Duvaldestin et al., 1982, 1983; Lebrault et al ., 1986). 
PHARMACOKINETICS AND PHARMACODYNAMICS OF VECURONIUM IN THE PAEDIATRIC 
AGE GROUP 
A pharmacokinetic study on 5 infants (3-11 months) and 5 children 
(1-5 years old) using a 3-compartment model showed a larger volume of 
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distribution at steady state (Vdss) and a larger mean residence time 
(MRT=Vdss/Cl, where Cl=total plasma clearance) in infants compared to 
children. The estimated steady-state plasma concentration that results 
in 50% depression of twitch tension (force-of-thumb adduction), 
CPss(SO) is lower in infants. All other pharmacokinetic parameters do 
not change with age. These results are similar to the age-related 
changes for d-tubocurarine (Fisher et al .• 1982, 1985a,b). 
Meistelman and coworkers published a pharmacokinetic study on 
vecuroni um in anaesthetized chi 1 dren. They studied vecuroni um and 
pancuroni um in 12 chi 1 dren of 3-8 years old under ha 1 othane ( 1 MAC) 
anaesthesia, using single twitch stimulation of the ulnar nerve and 
recording the resultant EMG of the thumb. A bolus of 0.1 mg/kg was 
given. The plasma clearance (Cl) and the volume of distribution at 
steady state (Vdss) are significantly greater in vecuronium than in 
pancuroni um ( Cl vee 2.8 and Cl pan 1. 7 ml /kg/min; Vdssvec 320 and pan 
203 ml/kg). 
No significant difference was found in the plasma concentration of 
either drug measured at 50 and 90% recovery, nor in the elimination 
half-life (Meistelman et al., 1985). Continuous infusion studies on 
vecuronium have only been made in adults (D'Hollander et al., 1982; 
Noeldge et al., 1984; Gramstad, Lilleaasen, 1985). 
Vecuroni um in paediatric anaesthesia has been studied by several 
investigators. Unfortunately all these studies were conducted under 
halothane anaesthesia. Although not as strongly potentiating as 
enflurane and isoflurane, halothane has a dose-dependent influence on 
the action of vecuronium (Leuwer, Dudziak, 1986). It remains unknown 
as to what dosages should be used in different age groups to cause 
equal effects on the neuromuscular system. 
Goudsouzian and colleagues stimulated the ulnar nerve with a 
train-of-four and measured the evoked thumb adduction. A cumulative 
dose-response curve was calculated for 40 children (2-9 years old) and 
adolescents (10-17 years old). Children were found to be significantly 
more resistant to the neuromuscular effect of vecuronium than 
adolescents. For children, respectively adolescents, the EDso is 33 
meg/kg, 23 meg/kg. the ED9o 51 meg/kg, 39 meg/kg and the ED95 60 
meg/kg, 45 meg/kg. The time from injection to maximal effect and the 
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time to full recovery of the first twitch compared to control do not 
show a statistically significant difference between the two age 
groups. The correlation between the MMG twitch height (T 1% of 
control) and train-of-four ratio values for vecuronium is found to be 
linear (r=0.91; p< 0.001) (Goudsouzian et al .• 1983b). 
Histamine release, which may be of concern in the use of atracurium. 
is of no importance in vecuronium. The onset times of both drugs are 
comparable but the recovery of a bolus dose of 120 meg/kg vecuronium 
from maximal twitch depression (Tl) to 95% recovery is slightly 
shorter than of a bolus dose of 600 meg/kg atracurium (atracurium 58.7 
min, vecuronium 44.6 min) (Goudsouzian et al .• 1986b,c). 
Pharmacodynamics of vecuronium were studied by Fisher and coworkers 
in 24 infants (age 7-45 weeks). 24 children (age 1-8 years) and 6 
adults (age 18-38 years) under halothane anaesthesia (0.9 MAC) with 
single twitches of the ulnar nerve, recording electromyogram and 
mechanomyogram of the thumb. Onset time (injection-peak effect) does 
not show a statistically significant difference between infants (1.5 
min) and children (2.4 min). However the onset is significantly more 
rapid in infants than in adults (2.9 min). The duration (injection-90% 
recovery of MMG) is significantly faster in infants (73 min) than in 
children (35 min) but not significantly faster than in adults (53 
min). Recovery rate (25-75% recovery) showes the same (infants 20 min. 
children 9 min and adults 13 min). The potency between the three age 
groups does not differ significantly (EDso infants 16.5 meg/kg. 
children 19.0 meg/kg and adults 15.0 meg/kg). A good carrel ati on is 
found for each age group between HlG and MMG (r=0.92) (Fisher. Miller, 
1983) . Schwartz and colleagues ( 1985) studied one group of children 
(1-10 years of age) during halothane anaesthesia with EMG and MMG They 
found the ED5o of vecuronium 22.4 meg/kg and the ED9o 36.8 meg/kg. 
Motsch and coworkers measured onset and recovery of vecuronium induced 
neuromuscular blockade in 21 infants (age 1 day-10 months) and 21 
children (age 1-6 years) under halothane anaesthesia (max. 1 vol. %). 
They found a significantly shorter onset time (injection-max. effect) 
and a l anger duration and recovery rate in infants as compared to 
children. For infants, respectively children. the onset time is 1.4 
min and 2.7 min, the duration (injection-25% recovery) 25 min and 18 
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min and the recovery rate (25-75%) 18 min and 10 min (Motsch et al., 
1985). 
A comparison between vecuroni urn and pancuroni urn in children ( 3-8 
years of age) was made by Meistelman and coworkers. Recovery is 
significantly faster in vecuronium. The duration of action (time from 
injection-90% recovery of T1) is 35 min for vecuronium and 92 min for 
pancuronium. And the recovery rate (25-75% recovery) for vecuronium is 
7 min and for pancuronium 28 min (Meistelman et al., 1985). In a 
similar study on 14 children of 4-8 years, using 1% halothane a bolus 
of 0.1 mg/kg vecuronium had an onset time of 3.1 min, a duration of 
action of 36.5 min and a recovery rate of 9.3 min. A calculated 
dose-response curve of 33 children of the same age shows an estimated 
ED5o 31 meg/kg, ED9o 55 meg/kg a~d ED95 64 meg/kg (Meistelman et al ., 
1986b) . 
Vecuronium exhibits most of the properties of the ideal 
neuromuscular blocking drug. Of the nondepolarizing blocking drugs 
atracurium and vecuronium are the only drugs of medium duration, and 
of these two vecuroni urn is the shortest acting. Neither drug causes 
ganglion blockade, sympathetic stimulation, vagolytic effects or vagal 
stimulation. Regarding histamine release, vecuronium is superior to 
Table I Adverse effects and pharmacodynamic parameters of d-tubocurarine, 
pancuronium, vecuronium and atracurium 
d-tubocurarine pancuronium vecuronium atracurium 
ganglion blockade ++ 
sympathetic stimulation ++ 
vagolytic effect ++ 
vagal stimulation 
histamine release +++ + 
onset time (sec) 221 215 168 161 
recovery rate (min) 59 32 10 11 
approximate relative 
potency by weight 1 4.7 5.6 1.1 
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atracurium. Considering all these factors, which are summarized in 
Tab 1 e I, vecuroni urn is the drug of choi se in the present i nvesti ga-
tions with paediatric patients. 
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IV THE POTENCY OF VECURONIUM IN NEONATES. INFANTS AND CHILDREN 
Vecuroni urn is a nondepol ari zing neuromuscular blocking agent with 
(in adults) an intermediate duration of action and a potency slightly 
greater than that of pancuronium. Potency can be expressed as the 
effective dose causing 50. 90 or 95% depression of an evoked muscle 
response (ED50• ED90• ED95l and as a dose-response curve. The ED5o. 
ED9o and ED95 of vecuronium in adults have been calculated by various 
i nvesti ga tors. 
In adults the effective doses were often calculated from a 
cumulative dose-response curve. In longer-acting relaxants this causes 
only minor deviations from the real value, but for vecuronium and 
atracurium it may cause larger deviations. Part of the previous 
dosage is already inactive by the time the next dose is given. Thus a 
cumulative technique then overestimates the effective dosages and 
causes a shift of the dose-response curve to the right. 
The published ED50 values of vecuronium in adults vary from 12.8 to 31 
meg/kg, the ED90 from 36.5 to 45 meg/kg and the ED95 from 39.6 to 56.7 
meg/kg, calculated using different techniques and procedures. 
In infants only Fisher and Miller (1983) have calculated an ED5o: 
16.5 meg/kg. The ED90 or ED95 for this age group cannot be found in 
the literature. In children Meistelman and coworkers calculated the 
ED50• ED9o and ED95 non-cumulative: respectively 31, 55 and 64 meg/kg 
(Mei stelman et al., 1986b). Goudsouzi an and coworkers (1983a) used a 
cumulative technique and found respectively 33, 51 and 60 meg/kg. 
Fisher gives the ED5o in children as 19.0 meg/kg. For adolescents 
Goudsouzian and coworkers (1983a) calculated the cumulative ED5o. ED9o 
and EDg5 to be, respectively, 23, 39 and 45 meg/kg. All paediatric 
studies were conducted under halothane anaesthesia (Table II). Thus 
one concludes that data are scattered and rare, especially in the 
infant-group. The aim of the study presented here is to determine 
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Table II Pharmacodynamic data of VECURONIUM in various age groups 
Investigator Age Anaesthesia Monitoring ED 5o Eo90 ED95 
technique (mcg/k'g) (meg/kg) (meg/kg) 
INFANTS 
Fisher and Miller (1983) 7-45 weeks 0.9 MAC Halothane M.M.G.-T1 16.5 
CHILDKEN 
Fisher and Miller (1983) 1-8 yr 0.9 MAC Halothane M.M.G.-T1 19.0 
Goudsouzian et al. 
(1983a) 2-9 yr 1.5% Halothane N.M.G.-TOF 33c 51c 60C 
Meistelman et al. 
(1986b) 4-8 yr 1% Halothane E.M.G.-T1 31 55 64 
(.)1 
();) ADOLESCENTS 
Goudsouzian et al. 10-17 yr 1.5% Ha 1 othane M.M.G.-TOF 23C 39c 45C 
(1983a) 
ADULTS 
~ibson et al. (1985) adult Fentanyl M.M.G.-T1 23.1 - 39.6 
Ording et al. (1985) 18-70 yr Halothane M.~1.G.-T1 25.7 36.5 
18-70 yr Fentanyl ~1.t4 . G . - T 1 28 40 
c curnul a ti ve dose response 
dose-response curves and to calculate the ED50,90 and 95 in various 
age groups, using a uniform experimental procedure. 
MATERIALS AND METHODS 
The study was approved by the Hospital Ethical Committee. 211 
healthy children, varying in age from 2 days-15 years old, body weight 
from 2.5-61 kg, were studied. All patients were free from respiratory, 
cardiovascular, neurological and infectious diseases. No patient 
suffered from metabolic, hepatic or renal disturbances. The 
gestational age of all patients younger than 5 years of age was 38 
weeks or more. Antibiotics and diazepam were strictly avoided. 
Each patient received an anaesthetic technique that was, so far as 
possible, standardized for these patients of such differing age 
groups (described bel ow) . The children were divided into 5 groups 
according to age: Group I 0-6 weeks old (n = 31); Group II 6-12 weeks 
old (n = 41); Group III 12 weeks-1 year old (n = 45); Group IV 1-6 
years old (n = 48) and Group V 6 years old and over (n = 46) (Table 
III). 
In group I 13 patients were operated for an ing~nal hernia and 6 
for pyloric stenosis. In group II the most frequent operations were 
herniotomy (n=34) and pyloromyotomy (n=4); and in group III herniotomy 
(n=22) and correction of cleft lip (n=7). In group IV 15 patients 
Table III Number, age, weight and sex distribution. Group I 0-6 weeks, group II 
6-12 weeks, group III 12 weeks-1 year, group IV 1-6 years and group v 
6-15 years 
Male Female 
Group 31 27.0 ± 12.6 days 3684 ± 603 g 24 7 
Group II 41 60.1 ± 11.4 days 4753 ± 769 g 31 10 
Group III 45 199 ± 93 days 7366 ± 1819 g 31 14 
Group IV 48 2.9 ± 1.5 years 14.6 ± 3.7 kg 41 7 
Group v 46 9.6 ± 2.2 years 34.2 ± 10.0 kg 31 15 
Values (age and weight) are mean± S.D. 
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underwent a herniotomy and 18 orchidopexia. In group V most patients 
were operated for undescended testes (n=20), 5 were operated on the 
middle ear and 4 underwent herniotomy. 
Premedication was not given to infants with a body weight less than 
3 kg. Infants with a body weight between 3 and 8 kg received 0.1 mg/kg 
atropine intramuscularly. Above 8 kg body weight 3 mg/kg trimeprazine 
(to a maximum of 60 mg) and 0.03-0.04 mg/kg atropine (to a maximum of 
1 mg) were given orally, 2 hours before the estimated time of 
induction. 
Genera 1 anaesthesia was induced with 5 mg/kg thiopentone i . v. and 
fentanyl, 3 meg/kg for children of 12 weeks and older (groups III, IV 
and V), and 1-3 meg/kg for infants younger than 12 weeks of age 
(groups I and II). Anaesthesia was maintained with 67% nitrous oxide 
in oxygen. Volatile halogenated agents were never used. Immediately 
after induction ventilation was assisted or controlled, using a mask. 
The aim was to keep the patient normocapnic (4.5-5% end expiratory 
C02). 
Immediately after induction surface electrodes for EMG recording 
were secured to the arm and 5 baseline electromyogram measurements 
were made (described later). Hereafter only once a single dose of 
vecuronium bromide was given intravenously. The intravenous canula was 
never in the same arm as the EMG-recording electrodes. 
Intubation was not attempted when the patient received a low dose of 
vecuronium. In this case all measurements were made first and intuba-
tion followed later after a second dose of vecuronium. The body tempe-
rature was kept normal and constant using such devices as a heating 
shield and a warm-water blanket. The ECG was continuously monitored in 
every patient. Surgery was started when all EMG measurements, taking 
approximately 10 min, were finished. 
The stimulus electrodes used in this study were small commercially 
available EEG electrodes. (fig. 9). They were firmly taped to the skin 
of the elbow to stimulate the ulnar nerve. A wet ground electrode was 
wound around the forearm (fig. 10). The recording electrodes were 
taped to the hypothenar eminence and the base of the fifth finger. 
These electrodes were homemade and consisted of a small circular link 
(diameter 3.5 mm) from a silver necklace soldered to a lead (fig. 11). 
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Fig. 9 Stimulus electrodes 
Fig. 10 Ground electrodes 
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Fig. 11 Recording electrodes 
Fig. 12 Arm with electrodes 
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Conductivity of sti mula ti ng and recording electrodes was improved by 
using EEG-gel. Care was taken to avoid contact of gel between one 
electrode and the other. The fingers were taped to the table to avoid 
gross movements of the hand (fig. 12). 
The electromyographic responses were measured with a r~edelec MS 91, 
a diagnostic electromyograph (fig. 13). With this machine the stimulus 
is adjustable in many ways. After stimulation of the ulnar nerve the 
resultant electromyogram was displayed on the oscilloscope of the 
Medel ec monitor. From the memory, every response can be written on 
paper by a slow recorder in the Medelec. Thereby artefacts can be 
sorted out easily (fig. 14). 
The ulnar nerve was stimulated by a single supramaximal, squarewave 
stimulus of 0.1 Hz with a duration of 0.2 msec. 
The negative deflection of the single EMG-response taken from the 
Medelec paper was used to estimate muscle relaxation. The mean of the 
first 5 control measurements served as control (0% relaxation). No 
measurable deflection was considered to correspond with 100% blockade 
of neuromuscular transmission. Every 10 seconds the degree of blockade 
(% of response compared to control value) was measured until it 
reached its maxi mum and was stable, or until recovery began. The 
maximum block was used for data analysis. 
Within each group all different dosages were used and applied in 
strict random order. Within each age group responses as % of maximal 
blockades into probits (Finney, 1952) were related to dosages 
transformed to natural logarithm (ln). 
Within each of the 5 groups the patients, receiving the same dosage 
vecuronium per kg bodyweight, were considered a sub-group (Table IV). 
The percentage response from all individuals in a sub-group were taken 
and their mean and standard deviation calculated. From the sub-groups 
results a dose-response curve was formed per age group. 
A common way of expression is to use a logarithmic scale for the 
dose-axis and a linear seale for the response-axis. The resultant 
curve will then be S-shaped. To simplify matters, the curve is 
transformed to a straight line when for the dose a log scale (elog) 
and for the response a probit seale is used. Thus a l og-probi t 
dose-response curve was estimated for all 5 groups. The l og-probi t 
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Fig. 13 Medelec MS 91, diagnostic electromyograph 
Fig. 14 
J ~r-------------------------------------------------
!--------1 
lcm 
Electromyogram in a neonate, 15 days old, weight 3475 grams. Control, 
50 sec and 5 min after administration of 0.1 mg.kg-1 vecuronium. Arrow 
indicates stimulus 
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Table IV Subgroups dose-response curves 
Number of individuals receiving dose (mg.kg-1) vecuronium 
Group n= 0.01 0.015 0.02 0.25 0.03 0.04 0.05 0.06 0.08 0.1 0.12 
31 1 5 5 0 5 0 5 5 5 0 0 
II 41 5 5 5 5 5 0 5 5 6 0 0 
III 45 5 5 5 5 5 5 5 5 5 0 0 
IV 48 0 5 6 5 6 0 5 5 5 6 5 
v 46 0 5 6 5 5 0 5 5 5 5 5 
dose-response curves are described by the formula y= a + bx. 
Linear equations were computed using the model y = a + bx, with y as 
the probit of the response; a as the intercept of the line with the 
y-axis; b as the slope of the line and x as the natural logarithm of 
the dose. The estimated value of x at a particular response level 
y-a. 
follows from x =-
b 
Thus the ED5o, the effective dose which results in 50% block, is 
obtained at the probit of 50%, which is y = 5.0; therefore 
5.0-a 
x = 1 n Eo50 = --· b 
The intercepts a and the slopes b were estimated from the data using a 
computer program (Quickstat 64, Scattergram). In a similar way the 
ED go and EDg5 were ca 1 cul a ted for each age group. To compare the 
results between the 5 age groups the 95% confidence limits for 
ln ED5o, ln EDgo and ln EDg5 were calculated using the formula 
ln EDp ± t * SE (ln EDp), where tis read from a Student-t table. The 
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SE (ln EDp), the standard error of the ln EDp was calculated using the 
formula: 
SE (ln EDp) (Tp - y)2 * [SE(b)]2 + b2 * [SE(y)] 2 
b4 
where Tp is the probit corresponding to the relevant percentage P (50, 
90, 95) andy is the mean of they-values in the group concerned. 
[SE(b)]2 residual variance, where xis the mean of the x-values in 
I: (x-x)2 
the group and 2 
L:(y- y) 
2 2 
- b I;(x- x) 
residual variance 
n - 2 
residual variance 
n 
RESULTS 
Data obtained from all patients were used for analysis, except for a 
few patients (not enlisted in Table IV), who were excluded due to 
technical failures. The resultant dose-response curves are shown in 
fig. 15. 
Using the above described formula, the log-probit dose-response 
curves were computed for the various groups: 
Group I y 12.49 + 2.08x n=31 
Group II y 12.18 + 1.98x n=41 
Group III y 12.57 + 2.13x n=45 
Group IV y 11.17 + 1.98x n=48 
Group v y = 11.28 + 2.00x n=46 
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Fig. 15 Dose-response (mg.kg-1-% EMG depression) curves for vecuronium. Group I 0-6 weeks, group II 6-12 v1eeks, group III 
12 weeks-1 year, group IV 1-6 years and group V 6-15 years 
The log-probit dose-response curves are given in figure 16. 
From the log-probit curves obtained for each of the 5 groups, the EDso 
(effective dose for 50% block), ED9o and ED95 plus the 95% confidence 
limits (in brackets) (fig. 17) were calculated using equations above. 
The Eo50 in group I is 0.027 mg/kg (0.024-0.031). 
The Eo50 in group II is 0.027 mg/kg (0.024-0.029). 
The Eo50 in group III is 0.028 mg/kg (0.025-0.032). 
The ED so in group IV is 0.044 mg/kg (0.040-0.048). 
The Eo50 in group v is 0.044 mg/kg (0.040-0.048). 
The Eo90 in group I is 0.050 mg/kg ( 0. 043-0.059) . 
The Eo90 in group II is 0.051 mg/kg (0.045-0.058). 
The Eo90 in group III is 0.052 mg/kg (0.044-0.056). 
The Eo90 in group IV is 0.084 mg/kg (0.074-0.096). 
The m90 in group v is 0.083 mg/kg (0.072-0.095). 
The Eo95 in group I is 0.060 mg/kg (0.050-0.072). 
The Eo95 in group II is 0.061 mg/kg (0.053-0.070). 
The Eo95 in group III is 0.062 mg/kg (0.051-0.074). 
The Eo95 in group IV is 0.101 mg/kg (0.087-0.117). 
The ED95 in group v is 0.099 mg/kg (0.085-0.116). 
A significant difference (p < 0.05) was found in effective doses 
between infants up to 1 year of age (groups I, I I and I I I) and 
children of 1-15 years of age (groups IV and V). Very similar results 
were found for neonates of 2 days-6 weeks of age (group I), infants of 
6-12 weeks of age (group II), 12 weeks-1 year of age (group III) on 
the one hand and for children of 1-6 years of age (group IV) and 
children and adolescents of 6-15 years of age (group V) on the other 
hand. Figure 15 and 17 clearly show these results. The EDso, ED9o and 
ED95 each show a similarity between group I, II and II I on the one 
hand and group IV and V on the other. 
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DISCUSSION OF THE METHODOLOGY 
Halogenated anaesthetic agents potentiate neuromuscular blockade 
induced by nondepolarizing muscle relaxants in a dose-dependent manner 
(see Chapter I I). Fisher cri ti ci zes other authors for using a fixed 
con centra ti on of ha 1 othane in different age groups. He states that 
anaesthetic conditions comparable for neonates, infants, children and 
adults are created by using equivalent, age adjusted MAC fractions of 
halothane (Fisher, Miller, 1983). However the MAC of halogenated 
agents is simply a mean value. Considerable interindividual 
differences may exist. The effect of halogenated agents on 
neuromuscular transmission is dose-dependant. But it is unknown as to 
whether using equivalent MAC fractions of halothane in patients of 
various ages provides equal effect on the pharmacodynamics and 
pharmacokinetics of vecuroni urn bromide. We therefore performed our 
study without the use of volatile anaesthetics. 
As with the anaesthetic technique, the stimulating and measuring 
techniques should also be standard in each group. Chosen is for a 
single twitch stimulation, because with this technique mainly 
postsynaptic effects are measured, whereas in train-of-four 
stimulation the presynaptic effect is more involved. In neonates the 
train-of-four ratio value without relaxants can be less than 100%, 
thus in this way even baseline measurements will be unequal. Stimulus 
duration is chosen to be 0.2 msec. Supramaximal stimulation is thereby 
obtained easier than with a stimulus of shorter duration. The abundant 
subcutaneous fat in infants can be especially troublesome in this 
respect. Longer stimulation is not advisable due to the possibility of 
repetitive firing. 
For quantitation of effect the electromyogram was chosen, being a more 
direct method than force of thumb adduction and for practical reasons 
being easier applied to infants and children. The amplitude of the 
negative deflection of the EMG-response was used to calculate the 
response. This is an easy method and has no disadvantages over calcu-
lating negative and positive amplitude or integration of the area 
under the curve (Pugh et al., 1984). 
The ulnar nerve is stimulated in order to be consistent with other 
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investigations, thus making comparison easier. The hypothenar muscles 
are measured because this location is less subject to movement arti-
fact caused by twitch-related movement of the hand. Moreover the 
hypothenar muscles are more superficial than the thenar muscles, thus 
the amount of tissue between muscles and recording electrodes is 
minimized, reducing the 1 i kel i hood of measurement artifacts (Weber, 
fvluravchick, 1986). Strict randomization of order of applying doses 
within age groups was followed to eliminate artefacts and bias in 
estimation of responses. 
DISCUSSION 
Confusion still remains concerning the sensitivity of children to 
nondepolarizing neuromuscular blocking agents. In the attempt to 
compare different age groups, it is essential to first clearly define 
what is meant by sensitivity. Does this refer to the correlation 
between dose and response, to the duration of the (clinical) effect or 
to both? In this study a comparison was made between five different 
age groups, ranging from neonates to adolescents, investigating the 
correlation between dose and response. We found a significant 
difference between children under 1 year of age and those over 1 year 
of age. 
The physiologic changes associated with maturation constitute a 
complex situation, with drugs localizing in different body regions, 
depending upon age. Although apparent volumes of distribution measured 
pharmacoki neti ca 11 y do not correspond to true body compartments, one 
would expect that age-related changes in body composition would be 
reflected in the measured distribution volumes. Most drugs distribute 
throughout the extracellular water before reaching their receptor 
sites. Particularly for drugs that are minimally distributed in the 
tissues (Bore us, 1982) , such as muscle relaxants (Roland, 1978) , the 
size of the extracellular water influences the drug concentration. The 
extracellular water decreases with age, especially in the first year 
of life (Widdowson, 1981). Thus as a rule, to achieve a given plasma 
concentration for drugs distributed in the extracellular water, a 
higher dose for each ki 1 ogram of body weight must be administered in 
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the neonate and infant compared to the adult (Martyn, 1986). These 
age-related variations in pharmacokinetics are further compounded by 
differences in receptor sensi ti vi ty between the various age groups. 
Whereas, on the basis of extracellular water, one would expect the 
neonate to be less sensitive to relaxant drugs given per kg body 
weight, on the basis of maturation of the neuromuscular system one 
vJoul d expect them to be more sensitive. Goudsouzi an ( 1980) found that 
maturation of neuromuscular transmission occurs in the first two 
months after birth. Crumrine and Yodlowski (1981) demonstrated a 
difference in myoneural function between that of infants less than 12 
weeks of age and that of older children and adults. It is thus not 
surprising that in our study infants up to 12 weeks of age (group I 
and II) are more sensitive to vecuronium. The balance between 
immaturity of the neuromuscular system and the increased extracellular 
water favors the former. Yet it is surprizing that the same results 
are found for infants from 12 weeks-1 year of age and that such a 
clear division is found between this age group and children of 1 year 
and older. Other mechanisms involving the neuromuscular transmission 
and/or organ function must therefore exist. 
Comparing results of different investigators it is essential to 
realise that the human adductor pollicis muscle contains approximately 
80% slow fibres and the abductor digiti mi nimi 52% (Johnson et al, 
1973) . Thus a difference may be found between studies using thenar 
muscles and those using hypothenar muscles. Yet Katz (1973) found a 
good correlation of EMG-% block in thenar and hypothenar muscles after 
suxamethonium administration. Our measurements were made on the 
hypothenar eminence. All undermenti oned studies were performed 
measuring EMG or MMG of the adductor pollicis muscle. 
Fisher and Miller (1983) found infants (7-45 weeks old, EDso 16.5 
meg/kg) to be more sensitive than children (1-8 years old, EDso 19.0 
meg/kg) and adults to be more sensitive than infants and children 
(EDso 15 meg/kg). But as a statistically significant difference did 
not exist, they concluded that vecuroni urn can be used in infants and 
children in doses similar to those recommended for adults during 
anaesthesia with nitrous oxide and 0.9 MAC halothane. 
Goudsouzian and coworkers (1983a) found children (2-9 years old, 
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ED 5o 33 meg/kg) si gnifi cantl y more resistant to the neuromuscular 
effects of vecuronium than adolescents (10-17 years old, ED5o 23 
meg/kg) during anaesthesia with 1-1.5% halothane, using a cumulative 
technique. Meistelman and colleagues (1986b) only measured one group 
of children (4-8 years old) and found the ED5o to be 31 meg/kg during 
1% halothane anaesthesia. No com pari son can be made because of the 
differences between the protocols. Different amounts of halothane were 
used, cumulative and noncumulative dose-response curve techniques and 
monitoring with either EMG or MMG were applied. The EMG response is 
likely to be less decreased than the MMG during halothane anaesthesia 
(Epstein and Epstein, 1973). However the ED 5o's found by Fisher with 
comparable techniques are comparatively low. 
In our study no halogenated agents were used. Thus the expected 
effective doses should be higher than those found in studies using 
halothane. The calculated effective doses came up to this expectation. 
There are no comparable studies in adults. Gibson and coworkers 
(1985) and Ording and colleagues (1985) both used fentanyl anaesthesia 
and MMG, single twitch compared to control. They found ED5o's 
respectively 23.1 and 28 meg/kg. Gibson and colleagues found the EDg5 
to be 39.6 meg/kg and Ording and coworkers the ED9o to be 40 meg/kg. 
Their ED5o's correlate well with the ones calculated in our study for 
neonates and infants. The ED9o and ED95 for the same groups are 
however much higher compared to the results of Gibson and Ordi ng. An 
explanation for this may be the slight difference in the slope of the 
dose-response curve causing a major difference in the far-ends of the 
curve. Thus a small difference in the slope of a curve with the same 
ED 5o causes a major difference in the calculated ED95. The effective 
doses calculated for groups IV and V are much higher than the ones 
published by Gibson and Ording for adults. Thus it is suggestive that 
the potency of vecuroni urn is higher in adults than in children and 
adolescents. In conclusion our study shows the potency of vecuronium 
in children up to 1 year of age to be higher than in children of 1-15 
years of age when given on the basis of body weight. 
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V ONSET TIME, DURATION OF ACTION AND RECOVERY RATE OF VECURONIUM 
IN NEONATES, INFANTS AND CHILDREN 
Vecuronium and atracurium are nondepolarizing neuromuscular blocking 
agents, developed in the search for the ideal muscle relaxant. Some of 
the requirements for such an ideal muscle relaxant are a fast onset, a 
short duration of action and a fast recovery. Although succinylcholine 
exerts such a pharmacodynamic profile it is a depolarizing drug and 
due to its many adverse effects, is not favoured in paediatric 
anesthesia. d-Tubocurarine and pancuronium, currently the most 
frequently used nondepolarizing muscle relaxants are characterized by 
a slow onset, a long duration of action and a slow recovery. 
Fisher and Miller (1983) and Motsch et al. (1985) have published 
data on the onset time (time from injection to maximal blockade) and 
recovery time of a vecuronium-induced neuromuscular blockade in 
infants. Both found a rapid onset after 70 meg/kg of respectively 1.5 
and 1.4 min. In children they found onset times of respectively 2.4 
and 2.7 min. More data on onset times regarding children, adolescents 
and adults have been published by various authors (Table V). The onset 
time appeared to be dependant on the administered dose: a small dose 
causing a longer onset time, whereas a larger dose resulted in a 
shorter onset time. But beyond a certain dose the onset time does not 
further decrease (Bencini, Newton, 1984). 
The clinical duration (the time from injection to a recovery of 75% 
blockade) after a dose of 70 meg/kg vecuronium, under halothane 
anaesthesia, was found to be 25 min in infants, 18 min in children 
(Motsch et al ., 1985) and 22 min in adults (Engbaek et al., 1984). 
Recovery of neuromuscular blockade is genera 11 y expressed as the 
time from injection or maximal effect to a certain percentage of 
recovery, or as the recovery rate (the time from 75-25% blockade). 
Here too the anaesthesia and monitoring technique play an important 
role. These factors and the given dose of relaxant vary considerably 
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Table V Pharmacodynamic data of VECURONIUM in various age groups 
Investigator Age Anaesthesia Monitoring Dose of Onset Recovery time Recovery 
technique vecuroni urn (min) (min) rate (min) 
(meg/kg) 5% 25% 90% 95% 25-75% 
of control 
INFANTS 
Fisher and Miller (1983) 7-45 weeks 0.9 MAC Halothane M.M.G.-T1 70 1.5 - - 73 - 20 
Motsch et al. (1985) 1 day-10 months Halothane E.M.G. 70 1.4 - 25 - - 18 
CHILDREN 
Fisher and Miller (1983) 1-8 yr 0.9 MAC Halothane M.M.G.-T1 70 2.4 - - 35 - 9 
Goudsouzian et al. 
(1983a) 1-10 yr 1-1.5% Halothane M.M.G.-T1 120 2.2 21.4 27.2 - 44.6 10.5 
-...! Nei stelman et al. 
(J) (1986b) 4-8 yr 1% Halothane E.M.G.-T1 100 3.1 - - 36.5 9.3 -
Hotsch 
et al. (1985) 1-6 yr Halothane E.M.G. 70 2.7 - 18 - - 10 
ADOLESCENTS 
Goudsouzian et al. 11-17 yr 
(1983a) 
1.5% Halothane M.M.G.-T1 80 1.8 19.7 26.5 - 48.1 13.1 
ADULTS 
8encini, Newton (1984) 20-70 yr Thiopentone M.M.G.-T1 100 3.4 - 21.0* - - 10 
Engbaek et al. (1984) adult Ketamine M.M.G.-TOF 73 2.5 - 22.2 -
Foldes et al. (1983) adult Fentanyl M.M.G.-T1 100 5.4 - 38.3* -
Robertson et al .(1983a) 18-65 yr Fentanyl M.M.G.-T1 129 2.6 - 39.0*52.6*- 13.8 
* from injection 
between different studies and make comparison of various studies 
almost impossible. The recovery rate seems to be the best method for 
comparing different age groups, because it is determined mainly by the 
disappearance of the muscle relaxant from the receptor side. Because 
vecuroni um-i nduced neuromuscular b 1 ockade does not show a cumulative 
effect (Agoston et al., 1980) the recovery rate is less dependant on 
the given dose of vecuronium as are recovery times taken from 
injection or maximal effect, which are also determined by other 
factors. 
All published paediatric studies were carried out under halothane 
anaesthesia. Onset time may be influenced by halogenated agents, 
because these agents potentiate the intensity of vecuroni um-i nduced 
neuromuscular blockade (Rupp et al., 1984) and because these agents 
have cardiovascular effects, changing muscle perfusion and other 
parameters. A decrease in hepatic blood flow (Gelman, 1976) can alter 
the distribution and elimination of the relaxant by the liver 
(Meistelman et al ., 1986b; Martyn, 1986). Thus halogenated agents also 
influence recovery. Cardiovascular effects of halogenated agents are 
more pronounced in neonates and infants than in children and adults. 
Thus one cannot presume that an equal inhalational concentration of 
halothane, even if this concentration is adjusted to the MAC for the 
age of the patient, has an equal effect on onset and recovery in the 
various age groups. Therefore this study, comparing onset and recovery 
of vecuroni um-i nduced neuromuscular b 1 ockade in different paediatric 
age groups, is performed without the use of volatile anaesthetic 
agents. 
MATERIALS AND METHODS 
The study was approved by the Hospital Ethical Committee. Latency 
times and on set times were measured in the 211 patients described in 
Chapter IV, given various single dosages and measured every 10 
seconds. The recovery phase was studied in 52 healthy children, others 
than the 211 described in Chapter IV, varying in age from 0 days to 13 
years of age and in weight from 2460 g -54 kg. All patients were free 
from respiratory, cardiovascular, neurological and infectious 
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diseases. No patient suffered from metabolic, hepatic or renal 
disturbances. The gestational age of all patients younger than 5 years 
of age was 38 weeks or more. Excluded from studies during the recovery 
phase were patients needing good surgical relaxation and patients 
scheduled for operations with an expected blood loss of more than 5% 
of the circulating blood volume. Antibiotics and diazepam were 
strictly avoided. 
The 52 children were divided into the same 5 age groups as described 
in Chapter IV. 
In group I 6 patients were operated for pyloric stenosis, 4 underwent 
a small laparotomy and 1 patient was operated for inguinal hernia. In 
group II 9 patients were operated for inguinal hernia and two for 
pyloric stenosis. In group III 7 patients underwent herniotomy, 1 
patient pyloromyotomy and 2 patients diagnostic procedure. In group IV 
and V 6 respectively 7 patients underwent orchidopexia and the others 
minor procedures. Number, mean age and weight and sex distribution of 
the patients of the different groups are shown in Table VI. 
Each patient received a standardized anaesthetic technique as far as 
is possible in patients of such varying ages. Premedication and 
induction were as described in Chapter IV. Anaesthesia was maintained 
with 67% nitrous oxide in oxygen, supplemented with small doses of 
fentanyl ( 1 meg/kg) or thiopentone ( 1-2.5 mg/kg) if necessary. 
Volatile anaesthetic agents were strictly avoided. 
Table VI Number, age, weight and sex distribution. Group I 0-6 weeks, group II 
6-12 weeks, group III 12 weeks-1 year, group IV 1-6 years and group V 
6-13 years 
Male Female 
Group 11 21.7 ± 14.9 days 3336 ± 729 g 7 4 
Group II 11 61.5 ± 12.0 days 4314 ± 465 g 9 2 
Group III 10 157 ± 85 days 6140 ± 1003 g 5 5 
Group IV 10 3.7 ± 1.7 years 16.3 ± 4.7 kg 8 2 
Group v 10 10.4 ± 1.7 years 37.9 ± 11.8 kg 9 1 
Values (age and weight) are mean± S.D. 
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Immediately after induction the EMG electrodes were secured to the 
arm and 5 baseline EMG measurements were made. Hereafter in all 52 
patients a single dose of 0.1 mg/kg vecuronium was given rapidly 
intravenously. The intravenous canula was never in the same arm as the 
EMG electrodes. Intubation was performed after 2-3 min. The patients 
were artificially ventilated and the percentage ex pi red C02 was kept 
close to 4% (Gould Godart capnograph mark II I) . The temperature was 
kept normal and constant using such devices as a heating shield, and a 
warm water blanket. All patients were monitored using ECG and 
plethysmograph. Blood pressure (Dynamap), inspiratory 02 and body 
temperature were also measured. 
The electromyographic responses were measured using the same method 
as described in Chapter IV. The stimulus frequency was however lower 
than 0.1 Hz. During the 5 five minutes of the recovery studies measu-
rements were done every half minute, thereafter every five minutes. 
This ensures that, even in the neonate, exhaustion never occured. 
Measurements were ceased on completion of the operation or after one 
hour, whichever came first. 
Measurements were made in patients of different age groups in random 
order. Patients fitting into the selection criteria were scheduled for 
operation,independant of their ages. All 52 patients were used for 
calculations of percentages of blockade for as long as measurements 
could be made during maximally 60 minutes after injection of 
vecuronium. The recovery of the blockade induced by 0.1 mg/kg 
vecuronium was expressed in various ways: graphically in time, as 
recovery rate and calculated as slope of the recovery curve, clinical 
duration and duration to 10 and 5% EMG depression. Within each group 
the percentages blockade at 5 min intervals were calculated for each 
individual. Because not all patients could be measured during 60 
minutes, the number of individuals used to calculate means and 
standard deviation decreased with increasing time after injection. 
As many patients in groups I, II and III did not reach 75% recovery 
(25% EMG depression) within the period measurements were taken, 
recovery was expressed as the slope of the recovery curve. For each 
individual the slope of the recovery was estimated from the data using 
a computer programme ( Epi stat). Once EMG depression was less than 
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maximal, the relation between time after the end of injection and the 
percentage EMG depression was expressed in a linear equation: 
y = a+ bx (y is the percentage EMG depression; a is the intercept of 
the line with they-axis; b is the slope of the recovery and xis the 
time after end of injection). 
Within each group the means of the individual a and b were calcula-
ted. The corresponding 95% confidence limits of b were calculated 
using the formula: 
mean ± Student t * SE (mean) 
(the degree of freedom is n-1). 
Using the formula x = y=a it is possible to calculate time from the 
b 
end of injection to a recovery of a certain percentage of EMG depres-
sion (a is the mean of the individual a's and b is the mean of the 
individual b's). The recovery times of the various age groups were 
calculated for a recovery to 75% (clinical duration), 10% and 5% EMG 
depression. Similarly the recovery rate was calculated for each age 
group. In groups IV and V the recovery rate was also measured in a 
conventional way, calculating the mean and standard deviation of the 
individual results. 
The latency times (end of injection to first effect) and the onset 
times (end of injection to maximal effect) were calculated as the mean 
of the individual times ± standard deviation per group and per dose. 
Comparisons were made using the 95% confidence limits. To prove a 
correlation between age and latency or onset time the Spearman rank 
correlation coefficient was calculated using the formula as described 
in Chapter VI. 
RESULTS 
Not all 52 measured patients were used for analysis of the slope of 
the recovery. Some neonates in groups I and I I did not recover a 
measurable amount in the available time thus had to be excluded: 2 
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patients of group I and 1 patient of group II were not included. One 
patient of group V was excluded because enflurane had to be adminis-
tered to the patient shortly after the start of the measurements. The 
measured recovery in the various age groups is shown in fig. 18. 
The calculated formula y =a+ bx is for: 
group I y 124.87 - 1.18 X n= 9 
group II y 132.17 - 1. 72 X n=10 
group III y 134.29 - 1. 74 X n=10 
group IV y 152.41 - 4.48 X n=10 
group v y 138.88 - 3.89 X n= 9 
The calculated slope of the recovery (b) with the 95% confidence 
limits is for groups I to V respectively: -1.18 ± 0.76, -1.72 ± 0.98, 
-1.74 ± 0.92, -4.48 ± 0.74 and -3.89 ± 0.55 (fig. 19). A statistically 
significant difference is seen between groups I, II and III on the one 
hand and groups IV and V on the other ( p < 0. 05). The recovery in 
children of one year of age and older is faster than the recovery in 
neonates and infants. 
The calculated times from the end of injection to 75% H1G depression 
(25% of control) are in groups I to V respectively 42.4, 33.2, 34.2, 
17.3 and 16.4 minutes. Measured from the available data, the time to 
75% EMG depression is in group I 40.0 ± 9.9 min (n=6), in group II 
36.4 ± 9.8 min (n=5), in group III 37.0 ± 15.7 min (n=7), in group IV 
18.7 ± 3.6 min (n=10) and in group V 18.0 ± 4.7 min (n=9). The calcu-
lated times to 10% EMG depression (90% of eontrol) are in groups I to 
V respectively 97.7, 70.9, 71.6, 31.8 and 33.1 min and to 5% EMG 
depression (95% of control) respectively 102.0, 74.0, 82.4, 32.9 and 
34.4 min (fig. 20). 
The recovery rates (75-25% EMG depression) are calculated in all 
five groups. One patient of group IV and one of group V did not 
recover to 25% EMG depression, so had to be excluded. In groups I to V 
the calculated recovery rates are respectively 42.5, 29.0, 28.8, 11.2 
and 12.9 min (fig. 21). The "conventional" recovery rate in group IV 
is 9.9 ± 2.4 min and in group V 10.9 ± 2.6 min (Table VII). 
The latency times with the 95% confidence limits for the ED5o of 
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Fig. 18 Recovery (minutes) of the% EMG depression after administration of 0.1 mg.kg-1 vecuronium. Group I 0-6 weeks, group 
II 6-12 weeks, group III 12 weeks-1 year, group IV 1-6 years and group V 6-13 years 
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Fig. 19 Calculated slope of the recovery (b) ± 95% confidence limits. Group 
0-6 weeks, group II 6-12 weeks, group III 12 weeks-1 year, group IV 
1-6 years and group V 6-13 years 
vecuronium are in groups I to V respectively 20 ± 14 sec, 26 ± 18 sec, 
15 ± 8 sec, 36 ± 15 sec and 42 ± 25 sec. No statistically significant 
differences were found, but the Spearman's rank correlation 
coefficient shows a positive correlation between age and latency time 
(alpha= 0.05). For the ED95 the latency times with the 95% confidence 
limits are in groups I to V respectively 13 ± 6 sec, 24 ± 6 sec, 20 ± 
8 sec, 25 ± 12 sec and 38 ± 15 sec (fig. 22). There is a statistically 
significant difference between groups I and V. There is a positive 
correlation between age and latency time (alpha= 0.02, Spearman). 
The onset times with the 95% confidence limits for the ED5o of 
vecuronium are in groups I to V respectively 188 ± 72, 232 ± 86, 250 ± 
80, 264 ± 22 and 288 ± 33 sec. No statistically significant differen-
ces were found between the various age groups. But the Spearman's rank 
correlation coefficient shows a positive correlation between age and 
onset time (alpha= 0.01). The ED95 doses show onset times with 95% 
confidence limits in groups I to V of 180 ± 95 sec, 218 ± 70 sec, 188 
± 69 sec, 252 ± 60 sec and 210 ± 64 sec (fig. 23). Neither a statisti-
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Fig. 20 Calculated recovery time (minutes) of the% H1G depression to 75, 10 and 5% E~IG depression after administration of 
0.1 mg.kg-1 vecuronium. Group I 0-6 weeks, group II 6-12 weeks, group III 12 weeks-1 year, group IV 1-6 years and 
group V 6-13 years 
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Calculated recovery rate in minutes (75-25% Ef~G depression) after 
administration of 0.1 mg.kg-1 vecuronium. Group I 0-6 weeks, group II 
6-12 weeks, group III 12 weeks-! year, group IV 1-6 years and group V 
6-13 years 
Table VII Recovery time (end of injection to 75, 10 and 5% EMG depression) and 
recovery rate ( 75-25% Ef~G depression) after 0.1 mg. kg-1 vecuroni urn 
in various age groups. Group I 0-6 weeks, group II 6-12 weeks, 
group III 12 weeks-! year, group IV 1-6 years, group V 6-15 ye~rs. 
Calculated (minutes) Measured (minutes) 
recovery time recovery rate recovery rate 
75% 10% 5% 
Group 42.4 97.7 102.0 42.5 
Group II 33.2 70.9 74.0 29.0 
Group III 34.2 71.6 82.4 28.8 
Group IV 17.3 31.8 32.9 11.2 9.9 ± 2.4 
Group v 16.4 33.1 34.4 12.9 10.9 ± 2.6 
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Fig. 22 Latency time in seconds (end of administration to first effect) ± 95% confidence limits after administration of 
effective dose causing 50 and 95% E~IG depression. Group I 0-6 weeks, group II 6-12 weeks, group III 12 weeks-
1 year, group IV 1-6 years and group V 6-15 years 
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effective dose causing 50 and 95% E~1G depression. Group I 0-6 weeks, group II 6-12 weeks, group III 12 weeks-
1 year, group IV 1-6 years and group V 6-15 years 
cally significant difference was found between the various age groups 
nor a correlation between age and onset time (Spearman). 
Hhen for the EDgs the times are calculated from end of injection to 
an EMG depression of 90% or over, the "onset" times with the 95% 
confidence limits in groups I to V are respectively 80 ± 59 sec, 190 ± 
104 sec, 116 ± 45 sec, 173 ± 68 sec and 188 ± 90 sec (fig. 24). Here a 
positive correlation is found between age and "onset" time (alpha 
0.05, Spearman). 
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Fig. 24 "Onset time" in seconds (end of administration to ~90% EMG depression) 
± 95% confidence limits after administration of effective dose causing 
95% EMG depression. Group I 0-6 weeks, group II 6-12 weeks, group III 
12 weeks-1 year, group IV 1-6 years and group V 6-15 years 
DISCUSSION 
Comparing the results of our study with others is difficult, because 
all published paediatric studies on vecuronium pharmacodynamics were 
conducted under halothane anaesthesia, whereas we strictly avoided 
halogenated agents. Fisher and Miller (1983) found after a single dose 
of 70 meg/kg vecuronium in 6 infants (7-45 weeks old) an onset time of 
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1.5 min, for 6 children (1-8 years old) 2.4 min and for adults 2.9 
min, using MMG. Motsch and colleagues (1985) found after the same 
dosage an onset time in infants (1 day-10 months old) of 1.4 min and 
in children (1-6 years old) of 2.7 min using EMG. 
For infants these onset times are much shorter than the onset times 
we found in groups I, II and III after a dose of 60 or 80 meg/kg. But 
if the "onset" time is considered to be the time from the end of 
injection to an EMG depression of 90% or over, the "onset" times of 
groups I and III resemble the results from Fisher and Miller, and 
~lotsch and colleagues. In group II this "onset" time is still much 
longer. 
For children the measured onset time in our study is also longer 
than that found by Fisher and Miller, but the onset time after 100 
meg/kg is comparable to the 3.1 min onset time after the same dosage, 
also using EHG-Tl measurements, as reported by Mei stelman and collea-
gues (1986b). Goudsouzian and coworkers (1983a) found for adolescents 
an onset time of 1.8 min after 80 meg/kg, using MMG. This again is a 
much shorter time than the result we found for adolescents after 100 
meg/kg, even when compared with our defined "onset" time. 
The onset time of vecuronium is dependant on the circulation time. 
Apart from normal individual differences, the circulation time is also 
influenced by the anaesthetic technique. Halogenated agents have sig-
nificant cardiovascular effects and also potentiate the neuromuscular 
blockade of vecuronium. Probably the shorter onset times under halo-
thane anaesthesia are caused by this potentiation and change in tissue 
perfusion. The differences in monitoring technique are also important. 
Besides the differences between EMG and MMG there may also be a diffe-
rence between the EMG onset measured in thenar and hypothenar eminence 
because of the different percentages of fast and slow fibres. 
He also chose to determine the "onset" time, the onset time to 90% 
blockade or over, because the measurement of the time course to 
maxi rna l effect is influenced by increasing the sensi ti vi ty of the 
recordings if the blockade approximates 100%. This difference in 
sensitivity of the recordings may also explain part of the differences 
in onset time between various studies. Healy et al. (1986) showed that 
the speed of onset of vecuronium, measuring EMG train-of-four response 
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under nitrous oxide-fentanyl anaesthesia, does not decrease when 
giving more than 60 meg/kg vecuronium. Thus in this way the different 
results of the various studies cannot be attributed to differences in 
doses of 70-100 meg/kg. Comparing the results of the five age groups 
in our study for the ED5o and ED95, no statistically significant 
differences are found. This may be due to the small numbers of 
measurements or to the chosen age limits. As we have the clinical 
impression that the onset time is shorter in younger patients, we 
also used the Spearman's rank correlation coefficient thus avoiding 
age limits. We succeeded in confirming our clinical impression with 
this method. For the ED95 the time to 90% injection (or over) proved 
to be a better choice than the time to maximal effect. The reason for 
this must be the high sensitivity of the Medelec monitor, which shows 
even the smallest increase in EMG blockade near the maximal blockade. 
Latency times in our study could not be compared with other studies, 
because no data were collected by other investigators. A study in 
adults by Gramstad and colleagues (1983) shows a latency time of 51 
seconds under nitrous oxide-fentanyl anaesthesia, using MMG. This is 
much longer than the latency times we found. Comparing our five age 
groups for latency time, mostly no statistically significant 
differences were found. But here again the Spearman's rank correlation 
coefficient confirmed our clinical impression: latency times increase 
with age. The most plausible explanation for this effect is the 
increase of circulation time with age. 
All recovery data in our study were obtained after a single dose of 
0.1 mg/kg vecuronium. In infants (7-45 weeks) Fisher and ~liller (1983) 
found a recovery to 10% blockade after 70 meg/kg of 73 min during 
halothane anaesthesia. This resembles our calculated results after 100 
meg/kg in groups II and III. As halothane potentiates vecuronium this 
explains this similarity. The recovery rate of Fisher and Mi 11 er in 
the infant group is 20 min, and Motsch and coworkers (1985) found 18 
min. Both recovery rates are shorter than the 29 min we found in 
groups II and III, yet in both studies halothane was administered. The 
recovery in children to 10% blockade after 0.1 mg/kg vecuronium was 
found to be 35 min by Meistelman and colleagues (1985). They also used 
E~lG and first twitch but also administered halothane. Yet their 
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fi~dings resemble our 32 min. The recovery rate we measured in 
children is 10 min. This equals the 10 min found by Goudsouzian and 
coworkers (1983a) after 80 meg/kg and by Motsch and colleagues (1985) 
after the same dose. Both groups of investigators used halothane. 
Neistelman and colleagues (1986b) found 9.3 min recovery rate after 
100 meg/kg. In adolescents our measured recovery rate of 11 min can be 
compared with the 13 min recovery rate found by Goudsouzian and 
coworkers, (1983a) (Table VII). 
Comparing our five age groups, group I shows the longest recovery 
expressed as recovery to 75%, 10% and 5% EMG depression and as 
recovery rate. In groups II and III the recovery times to 75%, 10% and 
5% EMG depression and the recovery rate resemble each other and are 
shorter than in group I. Obviously changes occur after the first 6 
weeks of life. Regarding the ED95's, as described in Chapter IV, there 
hardly is a difference between the infants in groups I, II and III. So 
the differences between groups I, II and III cannot be attributed to a 
relatively higher dosage in group I. Thus the differences must be due 
to differences in redistribution or elimination of the relaxant. Body 
composition changes rapidly in the first months of life (Widdowson, 
1981) and liver and kidney function become more mature. 
The children and adolescents (groups IV and V) show a much faster 
recovery than the infants. With age the extracellular fluid volume 
decreases and thus there is a proportional decrease in the di stribu-
tion volume of vecuronium. So to achieve a given plasma concentration, 
a higher dose per kg bodywei ght must be administered in the neonates 
and infants compared to older children and adults. Yet the sensitivity 
of the neuromuscular system also changes with age. The safety factor 
increases, thus the sensitivity of the system to vecuronium decreases 
with increasing age. These factors, together with the maturation of 
kidney and liver, influence the recovery from neuromuscular blockade. 
No si gni fi cant difference is found between groups IV and V but reco-
very is slightly faster in group IV. The faster recovery in children 
and adolescents compared to adults can be explained on the basis of 
enhanced hepatic excretion or metabolic clearance. The difference 
between groups I, II and III on the one hand and groups IV and V on 
tt1e other must partly be explained by the difference in the effective 
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doses. Administering 100 meg/kg to all groups means a relatively 
higher dose for groups I, II and III as demonstrated in the results in 
Chapter IV. 
Cal cul a ti ng the recovery times by formula was necessary due to a 
lack of sufficient patients measured to a recovery of 25% EMG depres-
sion. Yet there is a very good correlation between the calculated and 
measured recovery to 75% EMG depression in groups I to V and between 
the calculated and measured recovery rate in groups IV and V. 
In conclusion the latency and onset times determined in our study 
are generally longer than the times found in studies performed during 
halothane anaesthesia. In this study there is a positive correlation 
for the ED50 and the EDg5 between age and latency and onset times. The 
calculated recovery times to 75%, 10% and 5% EMG depression and the 
recovery rate correspond very well with the recovery times in other 
studies. There also is a good correlation between the calculated and 
measured data in our study. Recovery is slowest in neonates and 
slightly faster in infants. The recovery in children and adolescents 
is twice as fast as that in infants. 
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VI POTENCY OF VECURONIUM IN RELATION TO AGE 
Most studies concerning age-related differences in the pharmacolo-
gical properties of drugs force the investigator to choose various age 
groups. Knowledge of physiological changes can lead to a better choice 
of the age group limits. Such changes seldom occur overnight and one 
will always be confronted with the interindividual variation. By 
choosing the wrong age limits, significant differences, although 
actually present, can be missed. Setting the age-limits, thus, is an 
arbitrary matter. Therefore we chose a different approach here. 
Instead of correlating dose and response, a correlation between age 
and response for a certain dose was studied. 
MATERIALS AND METHODS 
The results of the dose-response studies of Chapter IV are used for 
this purpose. For three different doses of vecuronium (0.02, 0.05 and 
0.08 mg/kg), all available individuals in all 5 age groups were used 
and their age and maximal response plotted graphically. 
STATISTICAL METHODS 
The Spearman's rank correlation coefficient (rsl is calculated to 
estimate the association between age and response within a dose group, 
according to the formula: 6R 
rs = 1----
n(n2-l) 
R = 1.: d2, d is the difference in rank number between age and response 
and n is the total number of individuals. 
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RESULTS 
The Spearman rank correlation coefficient, calculated for the three 
chosen doses, shows a negative correlation between age and response. 
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Fig. 27 Maximal %ENG depression related to age (years) after administration of 0.08 mg.kg-1 vecuronium 
For 0.02 mg/kg (n=27) (fig. 25) rs = -0.34 (P < 0.10), for 0.05 mg/kg 
(n=25) (fig. 26) rs = -0.51 (P < 0.10) and for 0.08 mg/kg (n=26) (fig. 
27) r s = -0.70 ( P < 0.10) . Thus with increase in age there is a 
decrease in response with the same dose of vecuronium administered. 
DISCUSSION 
Ordinary dose-response curves of the potency of vecuroni urn show a 
si gni fi cant difference between infants less than one year old and 
children over one year of age (Chapter IV). Si nee this may hi de 
existing differences, avoiding arbitrary age limits is desired. The 
statistical analysis of the correlation coefficients by Spearman rank 
correlation, shows ample evi de nee that such a negative correlation 
between age and potency of vecuroni urn exists. This confirms the 
results of more conventional methods demonstrating the dependence of 
potency on age. 
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VII GENERAL DISCUSSION 
In spite of all attention paid to the problems concerned with the 
use of neuromuscular blocking agents, many questions remain to be 
answered concerning the use of these drugs in paediatric anaesthesia. 
We performed these studies on vecuronium pharmacodynamics because 
there is an obvious need, especially in anaesthesia for neonates and 
infants, for a nondepolarizing neuromuscular blocking agent, that is 
shorter-acting than the most frequently used agents, such as 
pancuronium and d-tubocurarine. Because of the total lack of side 
effects preference was given to vecuronium over atracurium. We limited 
our studies to the pharmacodynamics and did not extend to the 
pharmacokinetics, because micromeasurements of plasma concentrations 
of vecuronium are currently not possible. Moreover because of the high 
haematocrit of neonatal blood, more than 2 ml of blood is needed to 
obtain 1 ml of plasma. Samples must be taken within a period of a few 
minutes to construct a reliable curve in the distribution phase. Thus 
in neonates and infants a centra 1 1 i ne must be placed- to make this 
possible. A large number of samples have to be drawn for a 
pharmacoki netic study so in neonates a b 1 ood transfusion would be 
necessary. These considerations led us to the conclusion that it is 
not ethical to study plasma levels of vecuronium in neonates and 
infants so long as micromeasurements of the drug are not possible. 
Confusion still remains concerning children's sensitivity to the 
pharmacodynamics of muscle relaxants. Children are considered to be 
more (Long and Bachman, 1967), equal (Goudsouzian et al., 1974) or 
less (Goudsouzian et al., 1975) susceptible to the blocking action of 
neuromuscular blocking agents. The main cause of these confusing 
results is the total lack of uniformity in experimental procedure and 
1 ack of defi ni ti on of the term sensi ti vi ty. Si nee sensi ti vi ty changes 
during childhood a strict definition of age groups is also 
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indispensable. Besides this many factors such as like hypothermia, 
hypercarbia, hypocarbia, changes in acid-basebalance and administered 
drugs, can unintentionally influence the effects of nondepolarizing 
muscle relaxants. Therefore to compare the effects of vecuronium in 
various age groups we used a uniform procedure, keeping all variables 
as normal and constant as possible. Unfortunately a group of adults 
could not be included as our studies were conducted in a paediatric 
hospital, where adults are not admitted. 
Sensi ti vi ty can be expressed as potency or as duration of action. 
Both were determined in our study and led to the following results. 
The potency of vecuronium was expressed as the effective dose causing 
50, 90 or 95% depression of an evoked response (EDso. ED90• ED95) as 
measured by electromyography and as dose-response curves in the vari-
ous age groups. Each patient received only one single dose of 
vecuronium, since use of a cumulative dose-response technique may lead 
to an overestimation of the effective dosages of a blocking agent with 
an intermediate duration of action. 
Our results show a marked difference between infants up to 1 year of 
age (groups I, II and III) on the one hand and children above 1 year 
of age (groups IV and V) on the other. The EDso. 90 and 95 in groups 
IV and V are approximately 1.6 times the EDso. 90 and 95 of groups I, 
II and III. Yet there is a remarkable resemblance between the 
effective dosages between groups I, II and II I and the same is found 
between groups IV and V. The measured dose (mg/kg)-response (% EMG 
depression) curves and the calculated dose (ln mg/kg)-response (probit 
% EMG depression) curves show the same resemblance between groups I, 
II and III on the one hand and between groups IV and V on the other. 
The slopes of all five curves are practically equal. Thus the 
i nteri ndi vi dua 1 variation does not vary between the five age groups. 
The clinical impression that neonates and infants show the most 
interindividual variation could not be confirmed. 
The potency of vecuroni urn is partly determined by the amount of 
extracellular fluid as it distributes throughout the extracellular 
fluid before reaching the receptor sites (Boreus, 1982; Roland, 1978). 
A larger volume of distribution will result in a lower concentration 
and thus a 1 esser effect. Hhether this is the reason for the di fferen-
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ce we demonstrated in our study between the two groups aged below and 
above 1 year of age. cannot be answered because we could not perform 
pharmacokinetic studies. However the results of studies by Fisher and 
collegaues clearly demonstrated a larger distribution volume for 
vecuronium in infants (3-11 months of age) as compared to children 
(1-5 years of age) (Fisher et al.. 1985a,b). Similar results were 
found for atracurium by Brandom and colleagues for infants (1-8 months 
of age) and children (2-10 years of age) (Brandom et al .• 1986). 
Fisher and colleagues found the steady-state distribution volume of 
d-tubocurarine in neonates (0-2 months of age) to be significantly 
larger than in infants (2-12 months of age). and in infants to be 
larger than in children (1-12 years) (Fisher et al .• 1982). On basis 
of the ex trace ll ul ar fluid one would expect major changes to occur 
during the first year of life since. in this period the extracellular 
fluid is decreasing most (Widdowson. 1981). Thus with increasing age 
less drug per kg bodyweight is needed to reach the same plasma 
concentration. There may also be a difference in sensitivity of the 
neuromuscular system to the neuromuscular b 1 oc king action of 
vecuroni urn. 
The sensitivity of the neuromuscular system for other relaxants 
decreases with age. Maturation of the system occurs in the first 2-3 
months after birth (Goudsouzian. 1980; Crumrine. 1981). Such a point 
could be proven if the plasma concentrations at which a certain degree 
of neuromuscular blockade exists differ between the various age 
groups. For reasons already described we unfortunately were not able 
to demonstrate this. From the literature however it can be concluded 
that the ba 1 ance between i mma turi ty of the neuromuscular system and 
the increased extracellular fluid favors the former in neonates. Yet 
it is surprising that the same pharmacodynamic results were found in 
our study for infants from 12 weeks-! year of age but that yet another 
clear di vision is found between infants up to 1 year of age and 
children of 1 year and older. Therefore other unexplained mechanisms 
that undergo changes around the age of 1 year must exist and be 
involved in determining the potency of vecuronium. 
The only study on. vecuronium in infants (7-45 weeks of age) 
determining the ED5o was performed by Fisher and Miller (1983). They 
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compared infants with children (1-8 years of age) and adults under 
halothane anaesthesia using MMG. Adults have the lowest ED5o, followed 
by neonates and the highest ED5o is found in children. But no 
statistically si gni fi cant difference was found and all three age 
groups were considered equally sensitive. Perhaps if they had analyzed 
their data by Spearman's rank correlation they also would have found a 
sta ti sti call y significant correlation between potency and age. 
Goudsouzian and colleagues (1983a) found children (2-9 years of age) 
si gnifi can tl y more resistant to the neuromuscular effects of 
vecuronium than adolescents (10-17 years of age). 
More comparisons between various age groups were made for the 
effective dosages of atracurium. Neonates (1-28 days old) were studied 
by Meakin and coworkers ( 1987) and were found to be more sensitive 
than infants (1 month-1 year old), infants were found to be more 
sensitive than children (1-5 years old). Infants were also studied by 
Meistelman and colleagues (1986a). They found infants of 1-3 months of 
age more sensitive to atracurium than infants of 3-12 months of age. 
Brandom and coworkers (1984) found infants (1-6 months of age) to be 
equally sensitive as adolescents (11-16 years old) and both these age 
groups more sensitive to a tracuri urn than children ( 2-10 years old) . 
Goudsouzian and colleagues (1985) however found no difference in 
sensitivity to atracurium between infants (4 weeks-1 year old), 
children (1-10 years old) and adolescents (11-17 years old). 
Other muscle relaxants were studied by Goudsouzian and colleagues 
(1984). They found children (1-15 years old) more resistant than 
adults to pancuronium, metocurine and d-tubocurarine. The discrepancy 
in the results between the various relaxants, in our opinion, reveals 
that the potency of relaxants is multifactorially determined and not 
only dependent on extracellular volume and maturation of the 
neuromuscular junction. 
Sensitivity can also refer to (clinical) duration or recovery rate. 
We determined the time from the end of injection of 0.1 mg/kg 
vecuronium to 75, 10 and 5% EMG depression (recovery time), the time 
from 75-25% EMG depression (recovery rate) and the slope of the 
recovery in a 11 five age groups. The recovery was a 1 ways slowest in 
the neonates (group I), followed equally by the infants (groups II and 
102 
III). Recovery in children and ,adolescents (groups IV and V) was twice 
as fast. Using the calculated slope of the recovery as parameter the 
same results were found. Neonates recover very slowly, followed by the 
infants, and a much faster recovery is seen in children and 
adolescents. These results indicate that metabolism and/or excretion 
of vecuroni urn increases with age. It is assumed that this coincides 
with the optimalisation of liver and kidney function from neonates to 
adolescents, as described by various authors (Fisher et al., 1985a; 
Motsch et al., 1985). Vecuronium depends for its plasma elimination on 
redistribution (i.e. liver uptake), metabolism (liver) and excretion 
(hepatic and renal). Thus these factors may influence the duration of 
action of vecuronium. Since atracurium is reported to solely depend on 
Hofmann degradation in the plasma it is expected to be less 
age-dependent than vecuroni urn. This is however not confirmed by the 
literature (discussed below). 
Between groups I, I I and II I there is no significant difference in 
ED95. Thus the differences in recovery cannot be attributed to 
relatively higher doses, but may be due to differences in 
redistribution, elimination or other mechanisms. The faster recovery 
of groups IV and V is partly exp 1 a i ned by the fact that expressed as 
effective dose the given 0.1 mg/kg is less in groups IV and V. 
However the recovery rate for vecuronium is also much faster in groups 
IV and V. The recovery times to 90% of control found in infants (7-45 
weeks old) and in children (1-8 years old) by Fisher and Miller (1983) 
resemble our results, as does their reported recovery rate in 
children. However the recovery rate in infants reported by Fisher and 
Miller (1983) and Motsch and coworkers (1985) is faster than our 
calculated rate. Yet in both studies the recovery of children is 
significantly faster than the recovery of infants. Goudsouzian and 
colleagues (1983a) studied vecuronium in children (2-9 years old) and 
adolescents( 11-17 years old) and found no significant differences in 
recovery times between these two age groups. Generally no major 
differences are found in recovery times between children, adolescents 
and adults when comparing different studies. Yet no study. on 
vecuronium compares children or adolescents to adults. 
Atracurium is a nondepolarizing neuromuscular blocking agent that 
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has been unique 1 y designed to undergo degradation at physi o 1 ogi ca 1 
temperature and pH by a self-destroying mechanism ca 11 ed "Hofmann 
elimination" (Hughes, 1986). Thus, to reiterate, it is not surprising 
that Brandom and colleagues (1984) found totally different results in 
the comparison of recovery times of various age groups after 
atracurium and after vecuronium. The recovery times of neuromuscular 
transmission after atracurium administration to 25, 50 and 95% of the 
control value are significantly shorter in infants than in older 
children or adolescents at equal multiples of the ED95· Meretoja and 
Kalli (1986b) however found different results for atracurium. Although 
also using EMG and first twitch they found recovery times to 10 and 
100% significantly longer in patients under 10 kg body weight than in 
heavier patients. Also the recovery rate in patients under two months 
of age is significantly longer than in older infants, children and 
adolescents. Goudsouzian and coworkers (1983b) did not find a 
difference in recovery times of a tracuri urn between chi 1 dren (2-10 
years old) and adolescents (11-17 years old). 
The latency and onset times of vecuronium in our study show a 
positive correlation with age. Fisher and Miller (1983) and Motsch and 
colleagues (1985) also found the shortest onset times in infants. 
These results are very well explained by the decreased circulation 
time in infants. Goudsouzian and coworkers (1985) studied the onset 
time of atracurium. In infants (4 weeks-1 year old) the onset time is 
shorter than in children (2-10 years old) and adolescents (11-17 years 
old). No difference was found between children and adolescents. Lavery 
and Mirakhur (1984) compared onset times of atracurium, vecuronium and 
pancuronium in children of 1-14 years of age. The onset times of 
atracurium and vecuronium are similar and shorter than the onset time 
of pancuronium. 
From our studies the following clinical conclusions can be drawn: 
The potency of vecuronium in neonates and infants is higher than in 
children and adolescents. The effective dosages in chi 1 dren and 
adolescents are approximately 1.6 times the effective dosages in 
neonates and infants. Thus in children less than 1 year of age lower 
dosage should be used. 
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- The recovery times for vecuroni urn to a certain percentage of EMG 
depression and the recovery rate are very 1 ong in neonates. The 
recovery is faster in infants than in neonates. But the recovery in 
children and adolescents is twice as fast as the recovery in 
infants. 
- Long acting neuromuscular blocking agents such as d-tubocurarine and 
pancuronium must be considered obsolete for use in anaesthesia in 
children younger than one year of age, because of the very slow 
recovery of these drugs and the extreme sensitivity of neonates and 
infants to residual neuromuscular blockade. The drugs of choice in 
these age groups are the neuromuscular blocking agents of 
intermediate duration: vecuronium and atracurium. 
Latency and onset times of vecuronium increase with increasing age. 
In no age group did the onset time of vecuroni urn equal the fast 
onset of succinylcholine as reported in the literature (Cunliffe et 
al., 1986). 
No side effects of vecuronium were observed in any of the age 
groups. 
- Vecuronium is a safe drug for use in paediatric anaesthesia. 
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VIII SUMMARY 
Since the introduction of muscle relaxants in clinical paediatric 
anaesthesia (Chapter I) controversies concerning their potency and 
pharmacodynamic behaviour have remained. Over the years it has been 
demonstrated that various factors influence the neuromuscular 
transmission. During growth from newborn to adulthood many of these 
factors change due to the process of maturation. Apart from changes in 
organ functions such as liver and kidneys, body composition is also 
undergoing constant change. All these changes will influence on 
pharmacoki netic parameters and thus the pharmacodynamic behaviour of 
the neuromuscular blocking agents. Until recently information about 
the potency and pharmacodynamics of muscle relaxants in neonates and 
infants has been scarce due to the problems in quatitation of 
neuromuscular blockade in these age groups (Chapter II). With the 
development of electromyographic quantitation of neuromuscular 
blockade more information has become available but, due to remaining 
inconsistency in anaesthetic technique and many other factors, 
comparison between the various studies is almost impossible. This has 
led to different recommendations concerning the use of muscle 
relaxants in paediatric anaesthesia. For example, some authors 
consider neonates resistent to nondepolarizing muscle relaxants, 
others more sensitive and yet others consider them to be equa 11 y 
senti ti ve to these drugs as adults. In our study we determined and 
compared the potency and pharmacodynamic behaviour of vecuronium 
bromide, an intermediately long-acting nondepolarizing muscle 
relaxant, in the various paediatric age groups under similar 
anaesthetic conditions and using the same el ectromyographi c method 
(EMG) for quantitation of neuromuscular blockade. From the various 
currently used nondepolarizing muscle relaxants we decided to study 
vecuronium bromide because of its minimal adverse effects compared to 
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other relaxants (Chapter III). 
In the first clinical study we determined the potency of vecuronium 
bromide (Chapter IV). There was no significant difference in potency 
between neonates (birth-6 weeks) and infants of either 6-12 weeks 
and 12 weeks-12 months of age. Above that age the potency of vecuro-
nium was statistically significantly lower both in children (1-6 
years), and in older children and adolescents (6-14 years). There was 
no difference between the last two groups. In our opinion the potency 
of vecuronium as described in the literature for adults is slightly 
higher than the potency we found in the groups o 1 der than 1 year. It 
must be realised however that the age groups are arbitrary chosen. 
If, in order to avoid such an arbitrarily division of patients, a 
Spearman's rank correlation coefficient is calculated for potency and 
age, a negative correlation is found. This indicates that with 
increase in age a decrease in potency occurs (Chapter VI). 
In our second study we determined the pharmacodynamic parameters 
(latency time, onset time, duration of action and recovery rate) in 
the same age groups (Chapter V). A significant difference between the 
various age groups could not be demonstrated for latency time (time 
from administration to first EMG depression) and onset time (time from 
administration to maximal effect). However the Spearman's rank 
correlation coefficient demonstrated a positive correlation between 
these parameters and age. The duration of action, defined as time to 
recovery to 10% depression of the EMG was si gnifi cantl y 1 onger in 
neonates than in infants, which had values which were significantly 
1 onger than in chi 1 dren and adolescents. The same differences were 
found for the recovery times from administration to 75% and 5% EMG 
depression. The recovery rate (time from 75-25% EMG depression) was 
significantly longer in neonates as compared to infants, in which it 
was significantly longer than in children and adolescents. 
From our studies we believe it to be justified to conclude (Chapter 
VII) that neonates and infants are more susceptible to vecuroni urn 
bromide than children and adolescents. Recovery from vecuronium 
bromide in neonates is very slow, resulting in a long duration of 
action. Only above 1 year of age does vecuronium bromide reach its 
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intermediate duration of action, as is known in adults. 
Whether our results can be extrapolated to other neuromuscular block-
; ng agents is not known. However, due to the 1 arge vari abi 1 i ty in 
their rnetabo 1 i c and excretory pathways, as we 11 as in their pharmaco-
logical mechanism of action (pre-junctional and post-junctional 
effects) differences can be expected. 
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SAMENVATTING 
Si nds de i ntroducti e van spi errel axanti a in de kl i ni sche kinder-
anesthesie (hoofdstuk I) hebben er meningsverschillen bestaan over hun 
werkingssterkte en farmacodynamisch gedrag. Gedurende de afgelopen 
jaren is het aangetoond dat verschi1lende factoren de neuromuscu1aire 
transmissie beinv1oeden. Tijdens de groei van pasgeborene tot vo1was-
sene veranderen vele van deze factoren a1s gevolg van rijping. Daarbij 
veranderen orgaanfuncti es zoa 1 s die van lever en ni er en 1 i chaams-
samenste ll i ng voortdurend. Deze veranderi ngen hebben i nvl oed o p de 
farmacoki neti sche parameters en dus op het farmacodynami sche gedrag 
van spierre1axantia. Tot voor kort was informatie over de werkings-
sterkte en farmacodynami ek van spi erre l axanti a in neon a ten en zui ge-
lingen schaars door de bestaande problemen betreffende het kwantifice-
ren van spierverslapping in deze leeftijdsgroepen (hoofdstuk II). Met 
de ontwi kke1 ing van e1ektromyografi sche kwantifi cering van spi erver-
slapping kwam er meer informatie beschikbaar, maar vanwege de blijven-
de inconsequentie in anesthesie techniek en vele andere fatoren, is 
vergelijking tussen de verschillende onderzoeken bijna onmogelijk. Dit 
heeft geleid tot verschillende aanbevelingen voor het gebruik van 
spierre1axantia in de kinderanesthesie. Sommige schrijvers beschouwen 
pasgeborenen als resistent voor niet-depolariserende spierre1axantia, 
andere als gevoe1iger en weer andere beschouwen ze als even gevoelig 
voor deze farmaca a1s vo1wassenen. 
In ons onderzoek hebben we de werki ngsduur en het farmacodynami sche 
gedrag van vecuronium bromide, een midde1lang werkend niet-depolarise-
rend spi erre 1 axans, bepaal d in de verse hi 11 en de 1 eefti jdsgroepen van 
ki nderen onder dezelfde anesthesi e omstandi gheden en gebrui k makend 
van dezelfde elektromyografische methode (e.m.g.) ter kwantificering 
van spiervers1apping. Van de verschil1ende huidig gebruikte niet-depo-
lariserende spierre1axantia hebben we bes1oten tot het bestuderen van 
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vecuroni urn bromide vanwege Zl Jn mini rna l e bi jwerki ngen verge l eken met 
andere relaxantia (hoofdstuk III). 
In het eerste klini sche onderzoek hebben we de werkingssterkte van 
vecuroni urn bromide bepaal d ( hoofdstuk IV). Er was geen si gni fi cant 
verschil in werkingssterkte tussen pasgeborenen (geboorte tot 6 weken) 
en zuigelingen van 6 tot 12 weken en 12 weken tot 12 maanden oud. 
Boven die l eefti jd was de werki ngssterkte van vecuroni urn sta ti sti sch 
significant lager, zowel in kinderen van 1 tot 6 jaar als in kinderen 
van 6 tot 14 jaar. Er bestond geen verschi l tussen deze l aa tste twee 
groepen. Naar onze mening is de werkingssterkte van vecuronium in 
vo l wassenen zoa l s beschreven in de litera tuur, een beetje groter dan 
de werkingssterkte, die wij gevonden hebben in de groepen van 1 jaar 
en ouder. Men moet zich echter realiseren, dat leeftijdsgroepen 
arbitrair gekozen worden. Als men, om zo'n arbitraire verdeling van 
patienten te voorkomen, een Spearman's rangorde correlatie coefficient 
berekent voor werki ngssterkte en l eefti jd, dan vi ndt men een neg a ti eve 
correlatie. Dit betekent, dat met toename van de leeftijd een daling 
in werkingssterke optreedt (hoofdstuk VI). 
In ons tweede onderzoek hebben we de farmacodynami sche parameters 
(latentie tijd, inwerkingstijd, werkingsduur en herstelsnelheid) in 
dezelfde leeftijdsgroepen bepaald (hoofdstuk V). Een significant ver-
schil tussen de verschillende leeftijdsgroepen kon niet worden aange-
toond voor de latentietijd (tijdsduur van toediening tot eerste e.m.g. 
depressie) en inwerkingsduur (tijdsduur van toediening tot maximaal 
effect). De Spearman's rangorde correlatie coefficient toonde echter 
een posi ti eve correl ati e tussen deze parameters en l eefti jd aan. De 
werkingsduur gedefinieerd als tijdsduur van toediening tot een herstel 
tot 10% e.m.g. depressie, was significant langer in pasgeborenen dan 
in zuigelingen, die op hun beurt weer een significant langere 
werkingsduur vertoonden dan kinderen van een jaar en ouder. Dezelfde 
verschillen werden gevonden voor het herstel tot 75% en 5% e.m.g. de-
pressie. De herstelsnelheid (tijdsduur van 75 tot 25% e.m.g. depres-
sie) was significant langzamer in pasgeborenen vergeleken met zuige-
lingen en in zuigelingen weer significant langzamer dan in kinderen 
van 1 jaar en ouder. 
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Wij menen uit onze onderzoeken te mogen concluderen (hoofdstuk VII) 
dat pasgeborenen en zuigelingen gevoeliger zijn voor vecuronium 
bromide dan ki nderen van 1 jaar en ouder. Het hers tel van vecuroni urn 
bromide in pasgeborenen is erg l angzaam, resul terend in een lange 
werkingsduur. Pas boven de leeftijd van 12 maanden bereikt vecuronium 
een middellange werkingsduur zoals die gezien wordt bij volwassenen. 
Of onze resultaten geextrapoleerd kunnen worden naar andere spierre-
laxantia is onbekend. Echter, omdat er een grate variabiliteit bestaat 
in hun metabolisme en excretie, evenals in hun farmacologisch 
werkingsyrincipe (prejunctionele and postjunctionele effecten), kan 
een verschil verwacht worden. 
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